

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 February 2002 (21.02.2002)

PCT

(10) International Publication Number
WO 02/13798 A2

(51) International Patent Classification⁷: **A61K 31/00**,
31/505, 31/5355, 31/535, 31/4985, 31/495, 31/53, 38/28,
45/06, A61P 3/04, 3/06, 3/08, 3/10, 9/12, 9/10, 7/04

(21) International Application Number: PCT/IB01/01428

(22) International Filing Date: 6 August 2001 (06.08.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/224,928 11 August 2000 (11.08.2000) US
0030649.8 15 December 2000 (15.12.2000) GB
60/266,083 2 February 2001 (02.02.2001) US
0106465.8 15 March 2001 (15.03.2001) GB
0106468.2 15 March 2001 (15.03.2001) GB
0117134.7 13 July 2001 (13.07.2001) GB

(71) Applicant (for GB only): **PFIZER LIMITED** [GB/GB];
Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(71) Applicant (for all designated States except GB, US):
PFIZER INC. [US/US]; 235 East 42nd Street, New York,
NY 10017 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **FRYBURG, David**,
Albert [US/US]; Pfizer Global Research and Development,
Eastern Point Road, Groton, CT 06340 (US). **GIBBS, Earl**,

Michael [US/US]; Pfizer Global Research and Develop-
ment, Eastern Point Road, Groton, CT 06340 (US). **KOP-
PIKER, Nandan, Parmanand** [IN/GB]; Pfizer Global Re-
search and Development, Ramsgate Road, Sandwich, Kent
CT13 9NJ (GB).

(74) Agent: **WOOD, David, J.**; Pfizer Limited, Ramsgate Road,
Sandwich, Kent CT13 9NJ (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: TREATMENT OF THE INSULIN RESISTANCE SYNDROME

(57) Abstract: Use of a selective cGMP PDE5 inhibitor or a pharmaceutical composition thereof in the preparation of a medicament for the curative, palliative or prophylactic treatment of the insulin resistance syndrome wherein the insulin resistance syndrome means the concomitant existence in a subject of two or more of: dyslipidemia; hypertension; type 2 diabetes mellitus, impaired glucose tolerance (IGT) or a family history of diabetes; hyperuricaemia and/or gout; a pro-coagulant state; atherosclerosis; or truncal obesity wherein said use can occur alone or in combination with other agents to treat the insulin resistance syndrome or individual aspects of the insulin resistance syndrome.



WO 02/13798 A2

TREATMENT OF THE INSULIN RESISTANCE SYNDROME

This invention relates to the use of selective cGMP PDE5 inhibitors and in particular to selective cGMP PDE5 inhibitor compounds such as the compound
5 sildenafil for the treatment of the Insulin Resistance Syndrome.

The Insulin Resistance Syndrome as defined herein means the concomitant existence in a subject of two or more of: dyslipidemia, hypertension, type 2 diabetes mellitus or impaired glucose tolerance (IGT) or a family history of
10 type 2 diabetes mellitus, hyperuricaemia and/or gout, a pro-coagulant state, atherosclerosis, truncal obesity. A family history of type 2 diabetes mellitus as defined herein means having a first degree relation, sibling, parent or grandparent with type 2 diabetes mellitus. At the centre of the Insulin Resistance Syndrome, also known as "Syndrome X" and "Metabolic Syndrome" in the biomedical
15 literature is the common feature of tissue resistance to the action of insulin. This impaired biological response to insulin can be manifested in both the metabolic and vascular effects of insulin. Although there are monogenic syndromes of insulin resistance (IR), in which a definite gene has been identified as the cause of insulin resistance (such as leprechaunism), these are relatively rare. By contrast,
20 the more common presentation of the IRS is associated with obesity (particularly abdominal) and appears to be polygenic.

The early adaptive response to insulin resistance in many individuals having the insulin resistance syndrome produces compensatory
25 hyperinsulinaemia. As subjects with the insulin resistance syndrome become progressively insulin resistant, they manifest varying degrees of change in clinical parameters, including blood pressure, and/or increased levels of serum glucose, and/or cholesterol and/or triglycerides, and/or uric acid, and/or factors that increase coagulation. Once these clinical parameters have changed enough, the
30 patient with the IRS may differentially manifest well-recognised clinical conditions or diagnoses. These conditions include:

1. Hypertension (high blood pressure);
2. Impaired Glucose Tolerance (IGT) or type 2 diabetes mellitus (DM);

3. Hyperlipidemia or dyslipidemia, particularly (but not limited to) hypertriglyceridemia;
4. Hyperuricemia or Gout;
5. Hypercoagulability (defined as an abnormal, increased tendency for clots to form, particularly inside blood vessels);
6. Atherosclerosis.

These clinical conditions are well-recognised risk factors for cardio-vascular (coronary artery and cerebrovascular) disease.

10

It is difficult to estimate the prevalence of the Insulin Resistance Syndrome in the general populace due to both the diversity of the collective risk factors associated with the syndrome and the likelihood that many individuals affected by the Insulin Resistance Syndrome go undetected because they may exhibit no exterior symptoms and have no prior history of coronary heart disease. It is however possible to postulate that at a minimum the patient population at risk for the development of the Insulin Resistance Syndrome includes individuals with obesity, particularly truncal (abdominal) obesity. As obesity is an extremely common problem in the industrialized world and is associated with the clinical conditions mentioned above, it is very likely that the prevalence of IRS is very high. Considering this potential patient group alone forms an immense population potentially at risk for the development of complications of the Insulin Resistance Syndrome. For example in the United States in 1994, 23% of the population aged between 20 and 74 had hypertension, which accounted for 5 deaths per 100,000 population (1997). There will be an estimated 154,392,000 patients with diabetes world-wide in the year 2000. Of these, 15,000,000 will be in the US and 934,000 in the UK. The burden of disease for ischaemic heart disease for both sexes in the WHO region estimated for 1998 was 51,948,000 with a mortality of 7,375,000, constituting 13.7% of total mortality and ranking the highest in the mortality score. The burden of diabetes in both sexes in the WHO region estimated for 1998 was 11,668,000. Thus there exists a large medical need for an effective and safe oral therapy for the treatment of the Insulin Resistance Syndrome and prevention of the development of the Insulin Resistance Syndrome and its clinical consequences.

Resistance to the effects of insulin can also be observed in the diminished biological response of the endothelium to the vascular effects of insulin. That is, insulin promotes relaxation of blood vessel(s) at least in part through the action of nitric oxide. Nitric oxide generated in the endothelium then stimulates cGMP production in blood vessels and causes them to relax or dilate. This opening of the blood vessel allows more blood to flow, which is particularly important when more blood flow is needed to critical organs, like the heart. It has been demonstrated that there is a decreased release of nitric oxide (NO) from the endothelium of patients with insulin resistance. This decreased release of nitric oxide is not only from insulin, but also from other important vasodilators like acetylcholine. This so-called "endothelial dysfunction" contributes to the risk factors for cardiovascular disease which are associated with the Insulin Resistance Syndrome. It is thought that the vascular effect of insulin contributes to the effect of insulin to regulate metabolism, particularly, but not necessarily limited to, glucose metabolism.

In addition to the vascular actions of nitric oxide, NO also has direct effects on glucose uptake by skeletal muscle. That is, treatment with a NO-donor substance (nitroprusside) or an analogue of cGMP treatment in vitro increases glucose uptake (transport by GLUT4 glucose transporters). This vasodilation-independent pathway is described in G. J. Etgen, D. A. Fryburg and E. M. Gibbs in *Diabetes*, 46, 1997 pp. 1915-1919 the contents of which are incorporated herein by reference. It is proposed herein that, taken together, nitric oxide and cGMP likely have direct tissue level and vascular actions that influence, mediate, or mimic insulin's actions.

Further effects of impaired NO release by the endothelium include: an increase in vascular smooth muscle cell (VSMC) growth, proliferation and migration which are key steps in atherosclerotic plaque formation which can lead to stroke; an increase in platelet aggregation and adhesiveness (these effects on the platelet are also cGMP driven); an increase of lipid peroxidation and an effect on the inhibition of cell adhesion molecule expression including vascular cell adhesion molecule (VCAM-1), intracellular adhesion molecule (ICAM) and E-

selectin. Impaired endothelial NO release also impacts on the activity of inflammatory cytokines such as tumour necrosis factor- α , and the production of monocyte chemoattractant factor through decreased activity of the transcriptional activator nuclear factor κ B.

5

There are examples in which the treatment of factors contributing to IRS (e.g., obesity) or the treatment of IRS itself, such as with troglitazone or Rezulin, improves many of these clinical conditions. For example, dieting alone or pharmacotherapeutic agents that induce weight loss will decrease blood pressure, blood glucose and triglycerides. Agents that are designed to improve insulin sensitivity can also favorably alter blood pressure, lipids, and blood glucose.

It is proposed herein that successful diagnosis and treatment of patients with the Insulin Resistance Syndrome (as defined above) with a selective PDE5 inhibitor, especially sildenafil, may lead to clinically relevant improvements in blood pressure and/or blood sugar and/or lipids and/or uric acid, and/or procoagulant factors. This treatment can occur alone or in combination with other therapeutics that improve the IRS. Improvement in these clinical conditions should reduce the risk of the development of cardiovascular disease in some of these patients as well as other complications of these individual disorders (including, but not limited to diabetic neuropathy, nephropathy, and retinopathy).

The present invention is concerned with the search for a pharmaceutical treatment for individuals with the Insulin Resistance Syndrome as defined hereinbefore.

Whilst the Insulin Resistance Syndrome has many manifestations an important underlying mechanistic basis for the condition resides in a resistance to both the vascular and metabolic effects of insulin. It is also understood that the underlying pathology of vascular resistance in insulin resistance syndrome, is a diminished amount of NO produced by the endothelial cells in response to insulin. In the insulin pathway in insulin resistant individuals, there may be impaired signalling of insulin for glucose uptake (from the phosphatidylinositol 3-kinase, PI3K, pathway) which may lead to an inefficient GLUT-4 transport mechanism.

Whilst not wishing to be bound by any particular theory it is proposed herein that the pathway for the GLUT-4 transport mechanism and the cGMP-NO mechanistic pathway are somehow inter-linked.

- 5 For optimal functioning of the insulin signalling pathway for glucose uptake (via the GLUT-4 transport mechanism) it is preferable to have a normally functioning NO-cGMP pathway.

It is further proposed herein that amplification of the cGMP signal, using
10 cGMP specific PDE5 inhibitors in patients with the Insulin Resistance Syndrome would help to optimise the insulin glucose uptake signal and improve insulin action at key tissues. By making tissues more sensitive to insulin, it is thereby also proposed herein that improvements in the clinical parameters of the IRS would result, including, but not limited to improvements in:

15

1. Blood glucose control: In patients with diabetes mellitus or impaired glucose tolerance (IGT), it is postulated herein that an improvement in insulin resistance should result in a decrease in plasma glucose concentrations (either fasting or after an oral glucose tolerance test or a meal). In a related
20 manner, as regulated by the patient's pathophysiology, there will likely be an improvement in serum insulin concentrations in either the fasting state or after a glucose load or meal. These improvements in blood glucose control, should the subjects have type 2 diabetes mellitus, would manifest as improvements in measures of long-term blood glucose control, such as, but not limited to, haemoglobin A1c (glycosylated haemoglobin) or fructosamine; and/or
25

30

2. Blood pressure: It is postulated herein that an improvement in insulin resistance may also yield improvements in both systolic and diastolic blood pressure; and/or
3. Lipids: It is postulated herein that an improvement in insulin resistance may also yield improvements in serum lipids, including, but not limited to, serum cholesterol and triglycerides; and/or

4. Uric Acid: It is postulated herein that an improvement in insulin resistance may also yield improvements in serum uric acid; and/or
5. Coagulation Factors: It is postulated herein that an improvement in insulin resistance would also restore, towards normal, factors that worsen the procoagulant state.

These improvements in insulin resistance (improved sensitivity) may or may not be accompanied by improvement in compensatory hyperinsulinaemia and hence improve the components of the Insulin Resistance Syndrome.

cGMP PDE 5 inhibitors prevent the effect of the phosphodiesterase 5 enzyme that converts cGMP to inactive GMP thus increasing the amount of accumulated cGMP. This accumulation would amplify the vasodilatory, metabolic, and anti-atherogenic effects of the available nitric oxide and insulin. It is postulated herein that this amplification action (of plasma cGMP) will mitigate the adverse effects associated with the IRS and improve one or more of the associated conditions.

Sildenafil (Viagra[®]) is an orally-active, potent and selective inhibitor of cyclic guanosine monophosphate (cGMP) specific phosphodiesterase type 5 (PDE5) which is the predominant PDE5 isoenzyme in human corpora cavernosa. Consequently, sildenafil has been shown to be effective in the treatment of male erectile dysfunction. It is proposed herein that by inhibiting the cGMP to GMP conversion pathway, selective cGMP PDE5 inhibitors and in particular Sildenafil increase the intracellular concentrations of nitric oxide (NO) derived cGMP. This accumulation would amplify the vasodilatory, metabolic, and anti-atherogenic effects of the available nitric oxide and insulin.

Thus according to a first aspect of the present invention we provide a method of treating the insulin resistance syndrome which comprises treating the patient with an effective amount of a selective cGMP PDE5 inhibitor or a pharmaceutical composition thereof wherein the insulin resistance syndrome means the concomitant existence in a subject of two or more of: dyslipidemia;

hypertension; type 2 diabetes mellitus, impaired glucose tolerance (IGT) or having a family history of diabetes; hyperuricaemia and/or gout; a pro-coagulant state; atherosclerosis; or truncal obesity.

5 Depending on the individual with IRS, the method may have a beneficial effect on one or more of conditions associated with the IRS as defined herein. Thus according to a further aspect the present invention additionally provides a method of treating type 2 diabetes mellitus or impaired glucose tolerance (IGT); or dyslipidemia, or hyperuricemia and/or gout, or the procoagulant state which
10 comprises treating the patient with an effective amount of a cGMP PDE5 inhibitor or a pharmaceutical composition thereof. According to a yet further aspect the present invention additionally provides a method of treating type 2 diabetes mellitus or impaired glucose tolerance (IGT) in a patient wherein the patient does not have other risk factors associated with the IRS which comprises treating the
15 patient with an effective amount of a selective pyrazolopyrimidinone cGMP PDE5 inhibitor as defined hereinafter or a pharmaceutically acceptable salt or a pharmaceutical composition thereof. According to a further aspect the present invention additionally provides a method for the prevention of progression in a subject of impaired glucose tolerance (IGT) to type 2 diabetes mellitus via
20 treatment of a patient in need of such treatment with an effective amount of a selective pyrazolopyrimidinone cGMP PDE5 inhibitor as defined hereinafter or a pharmaceutically acceptable salt or a pharmaceutical composition thereof.

 According to a second aspect the present invention provides a method of
25 treating the insulin resistance syndrome which comprises treating the patient with an effective amount of a cGMP PDE5 inhibitor or a pharmaceutical composition thereof wherein the insulin resistance syndrome means the concomitant existence in a subject of three or more of: dyslipidemia; hypertension; type 2 diabetes mellitus, impaired glucose tolerance (IGT) or having a family history of diabetes;
30 hyperuricaemia and/or gout; a pro-coagulant state; atherosclerosis; or truncal obesity.

 According to a third aspect the present invention provides a method of treating the insulin resistance syndrome which comprises treating the patient with

an effective amount of a cGMP PDE5 inhibitor or a pharmaceutical composition thereof wherein the insulin resistance syndrome means the concomitant existence in a subject of four or more of: dyslipidemia; hypertension; type 2 diabetes mellitus, impaired glucose tolerance (IGT) or having a family history of diabetes; 5 hyperuricaemia and/or gout; a pro-coagulant state; atherosclerosis; or truncal obesity.

According to a fourth aspect the present invention provides a method of treating the insulin resistance syndrome which comprises treating the patient with 10 an effective amount of a cGMP PDE5 inhibitor or a pharmaceutical composition thereof wherein the insulin resistance syndrome means the concomitant existence in a subject of five or more of: dyslipidemia; hypertension; type 2 diabetes mellitus, impaired glucose tolerance (IGT) or having a family history of diabetes; hyperuricaemia and/or gout; a pro-coagulant state; atherosclerosis; or truncal 15 obesity.

According to a fifth aspect the present invention provides a method of treating the insulin resistance syndrome which comprises treating the patient with an effective amount of a cGMP PDE5 inhibitor or a pharmaceutical composition 20 thereof wherein the insulin resistance syndrome means the concomitant existence in a subject of : dyslipidemia; hypertension; type 2 diabetes mellitus or impaired glucose tolerance (IGT); and truncal obesity.

According to a sixth aspect the present invention provides a method of 25 treating the insulin resistance syndrome which comprises treating a patient with type 2 diabetes mellitus, impaired glucose tolerance (IGT) or a family history of diabetes and at least one of the following conditions : dyslipidemia; hypertension; hyperuricaemia and/or gout; a pro-coagulant state; atherosclerosis; or truncal obesity with an effective amount of a cGMP PDE5 inhibitor or a pharmaceutical 30 composition thereof.

According to a seventh aspect the present invention provides a method of treating the insulin resistance syndrome which comprises treating a patient with type 2 diabetes mellitus, impaired glucose tolerance (GT) or a family history of

diabetes and at least two of the following conditions : dyslipidemia; hypertension; hyperuricaemia and/or gout; a pro-coagulant state; atherosclerosis; or truncal obesity with an effective amount of a cGMP PDE5 inhibitor or a pharmaceutical composition thereof.

5

According to an eighth aspect the present invention provides a method of treating the insulin resistance syndrome which comprises treating a patient with type 2 diabetes mellitus, impaired glucose tolerance (IGT) or a family history of diabetes and at least three of the following conditions : dyslipidemia; hypertension;
10 hyperuricaemia and/or gout; a pro-coagulant state; atherosclerosis; or truncal obesity with an effective amount of a cGMP PDE5 inhibitor or a pharmaceutical composition thereof.

According to a ninth aspect the present invention provides a method of
15 treating the insulin resistance syndrome which comprises treating a patient with type 2 diabetes mellitus, impaired glucose tolerance (IRS) or a family history of diabetes and at least three of the following conditions : dyslipidemia; hypertension; hyperuricaemia and/or gout; a pro-coagulant state; atherosclerosis; or truncal obesity with an effective amount of a cGMP PDE5 inhibitor or a pharmaceutical
20 composition thereof.

According to a tenth aspect the present invention provides a method of treating the insulin resistance syndrome which comprises treating a patient with type 2 diabetes mellitus, impaired glucose tolerance (IGT) or a family history of
25 diabetes and at least four of the following conditions : dyslipidemia; hypertension; hyperuricaemia; a pro-coagulant state; atherosclerosis; or truncal obesity with an effective amount of a cGMP PDE5 inhibitor or a pharmaceutical composition thereof.

30 According to an eleventh aspect the present invention provides a method of treating the insulin resistance syndrome which comprises treating a patient with type 2 diabetes mellitus, impaired glucose tolerance (IGT) or a family history of diabetes and at least five of the following conditions : dyslipidemia; hypertension; hyperuricaemia and/or gout; a pro-coagulant state; atherosclerosis; or truncal

obesity with an effective amount of a cGMP PDE5 inhibitor or a pharmaceutical composition thereof.

According to a further aspect the present invention additionally provides a
5 method for the reduction in the risk of the development of cardiovascular disease
in patients identified as being at risk of developing the insulin resistance syndrome
wherein said method comprises treating the patient with an effective amount of a
cGMP PDE5 inhibitor or a pharmaceutical composition thereof and wherein a
patient at risk of developing the insulin resistance syndrome is defined as an
10 individual having at least one of the following conditions: dyslipidemia;
hypertension; type 2 diabetes mellitus, impaired glucose tolerance (IGT) or having
a family history of diabetes; hyperuricaemia and/or gout; a pro-coagulant state;
atherosclerosis; or truncal obesity and whom on subsequent analysis is found to
have at least two of said conditions.

15

According to a further aspect the present invention provides a method for
treating the insulin resistance syndrome as defined hereinbefore in a polygenic
insulin resistant individual which comprises treating the individual with an effective
amount of a cGMP PDE5 inhibitor or a pharmaceutical composition thereof.

20

Suitable PDE5i's for use in the pharmaceutical compositions according to
the present invention are the cGMP PDE5i's hereinafter detailed. Particularly
preferred for use herein are potent and selective cGMP PDE5i's.

25 Suitable cGMP PDE5 inhibitors for the use according to the present invention
include:

the pyrazolo [4,3-d]pyrimidin-7-ones disclosed in EP-A-0463756; the pyrazolo
[4,3-d]pyrimidin-7-ones disclosed in EP-A-0526004; the pyrazolo [4,3-d]pyrimidin-
30 7-ones disclosed in published international patent application WO 93/06104; the
isomeric pyrazolo [3,4-d]pyrimidin-4-ones disclosed in published international
patent application WO 93/07149; the quinazolin-4-ones disclosed in published
international patent application WO 93/12095; the pyrindo [3,2-d]pyrimidin-4-ones
disclosed in published international patent application WO 94/05661; the purin-6-

ones disclosed in published international patent application WO 94/00453; the pyrazolo [4,3-d]pyrimidin-7-ones disclosed in published international patent application WO 98/49166; the pyrazolo [4,3-d]pyrimidin-7-ones disclosed in published international patent application WO 99/54333; the pyrazolo [4,3-d]pyrimidin-4-ones disclosed in EP-A-0995751; the pyrazolo [4,3-d]pyrimidin-7-ones disclosed in published international patent application WO 00/24745; the pyrazolo [4,3-d]pyrimidin-4-ones disclosed in EP-A-0995750; the compounds disclosed in published international application WO95/19978; the compounds disclosed in published international application WO 99/24433 and the compounds disclosed in published international application WO 93/07124.

The pyrazolo [4,3-d]pyrimidin-7-ones disclosed in published international application WO 01/27112; the pyrazolo [4,3-d]pyrimidin-7-ones disclosed in published international application WO 01/27113; the compounds disclosed in EP-A-1092718 and the compounds disclosed in EP-A-1092719.

Preferred selective type V phosphodiesterase inhibitors for the use according to the present invention include:

5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (sildenafil) also known as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulphonyl]-4-methylpiperazine (see EP-A-0463756);

5-(2-ethoxy-5-morpholinoacetylphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (see EP-A-0526004);

3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-n-propoxyphenyl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (see WO98/49166);

3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (see WO99/54333);

(+)-3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxy-1(R)-methylethoxy)pyridin-3-yl]-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, also known as 3-ethyl-5-{5-[4-ethylpiperazin-1-ylsulphonyl]-2-[(1R)-2-methoxy-1-methylethyl]oxy}pyridin-3-yl]-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]
 5 pyrimidin-7-one (see WO99/54333);

5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-[2-methoxyethyl]-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, also known as 1-{6-ethoxy-5-[3-ethyl-6,7-dihydro-2-(2-methoxyethyl)-7-oxo-2H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-pyridylsulphonyl}-4-ethylpiperazine (see WO 01/27113, Example 8);

5-[2-*iso*-Butoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(1-methylpiperidin-4-yl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (see WO
 15 01/27113, Example 15);

5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-phenyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (see WO 01/27113, Example 66);

20 5-(5-Acetyl-2-propoxy-3-pyridinyl)-3-ethyl-2-(1-isopropyl-3-azetidiny)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (see WO 01/27112, Example 124);

5-(5-Acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidiny)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (see WO 01/27112, Example 132);

25

and pharmaceutically acceptable salts, polymorphs and solvates thereof.

Thus according to a preferred aspect the present invention provides for the use of a selective pyrazolopyrimidinone cGMP PDE5 inhibitor or a pharmaceutical
 30 composition thereof in the preparation of a medicament for the curative, palliative or prophylactic treatment of the insulin resistance syndrome in a mammal wherein the selective cGMP PDE5 inhibitor is selected from : sildenafil, 5-(2-ethoxy-5-morpholinoacetylphenyl)-1-ethyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one,
 3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-n-

propoxyphenyl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-*d*]pyrimidin-7-one, 3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-*d*]pyrimidin-7-one, 5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-2,6-dihydro-7H-pyrazolo[4,3-*d*]pyrimidin-7-one and 1-[[3-(3,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-*f*]-as-trizin-2-yl)-4-ethoxyphenyl]sulphonyl]-4-ethylpiperzine or a pharmaceutically acceptable salt, solvate, pro-drug or polymorph thereof.

More particularly, the present invention provides a method of treating a patient with the insulin resistance syndrome which comprises treating the patient with an effective amount of a selective pyrazolopyrimidinone cGMP PDE5 inhibitor selected from sildenafil, 5-(5-Acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidiny)-2,6-dihydro-7H-pyrazolo[4,3-*d*]pyrimidin-7-one or 5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-2,6-dihydro-7H-pyrazolo[4,3-*d*]pyrimidin-7-one or pharmaceutically acceptable salts, solvates, pro-drugs, polymorphs or pharmaceutical compositions thereof.

The invention also provides for the use of a selective pyrazolopyrimidinone cGMP PDE5 inhibitor and in particular sildenafil, 5-(5-Acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidiny)-2,6-dihydro-7H-pyrazolo[4,3-*d*]pyrimidin-7-one or 5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-1-(2-methoxyethyl)-1,6-dihydro-7H-pyrazolo[4,3-*d*]pyrimidin-7-one for the manufacture of a composition for the treatment or prophylaxis of the insulin resistance syndrome.

25

According to a further aspect the present invention additionally provides for the use of sildenafil or a pharmaceutically acceptable salt or of a pharmaceutical composition thereof for the treatment of the insulin resistance syndrome in a subject having type 2 diabetes mellitus, impaired glucose tolerance (IGT) or having a family history of diabetes and at least one of the following conditions : dyslipidemia; hypertension; hyperuricaemia and/or gout; a pro-coagulant state; atherosclerosis; or truncal obesity.

30

According to a yet further aspect the present invention additionally provides for the use of sildenafil or a pharmaceutically acceptable salt or of a pharmaceutical composition thereof for the treatment of the insulin resistance syndrome in a subject having type 2 diabetes mellitus, impaired glucose tolerance
5 (IGT) or having a family history of diabetes and one or more of the following conditions : dyslipidemia; hypertension; or truncal obesity.

According to a yet further still aspect the present invention additionally provides for the use of sildenafil or a pharmaceutically acceptable salt or of a
10 pharmaceutical composition thereof for the treatment of the insulin resistance syndrome in a subject having type 2 diabetes mellitus, or impaired glucose tolerance (IGT) or having a family history of diabetes and dyslipidemia and hypertension and truncal obesity.

15 Preferred pharmaceutically acceptable salts of sildenafil for use herein are sildenafil citrate and sildenafil mesylate.

The cGMP PDE5 inhibitors as defined herein and in particular potent and selective cGMP PDE5 inhibitors and most particularly sildenafil, 5-(5-Acetyl-2-
20 butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidiny)-2,6-dihydro-7H-pyrazolo[4,3-
d]pyrimidin-7-one or 5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-1-(2-methoxyethyl)-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one are additionally useful for the manufacture of a composition for the treatment or prophylaxis of endothelial dysfunction.

25

Further type V PDE inhibitors suitable for use herein include:

(6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl) -
pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione (IC-351), i.e. the compound of
30 examples 78 and 95 of published international application WO95/19978, as well as the compound of examples 1, 3, 7 and 8;

2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one (varденаfil) also known as 1-[[3-(3,4-dihydro-5-

methyl-4-oxo-7-propylimidazo[5,1-f]-as-triazin-2-yl)-4-ethoxyphenyl]sulphonyl]-4-ethylpiperazine, i.e. the compound of examples 20, 19, 337 and 336 of published international application WO99/24433; and

- 5 the compound of example 11 of published international application WO93/07124 (EISAI); and

compounds 3 and 14 from Rotella D P, *J. Med. Chem.*, 2000, 43, 1257.

- 10 Still other type cGMP PDE5 inhibitors useful in conjunction with the present invention include: 4-bromo-5-(pyridylmethylamino)-6-[3-(4-chlorophenyl)-propoxy]-3(2H)pyridazinone; 1-[4-[(1,3-benzodioxol-5-ylmethyl)amiono]-6-chloro-2-quinazolinyl]-4-piperidine-carboxylic acid, monosodium salt; (+)-cis-5,6a,7,9,9a-hexahydro-2-[4-(trifluoromethyl)-phenylmethyl-5-methyl-cyclopent-4,5]imidazo[2,1-b]purin-4(3H)one; furazlocillin; cis-2-hexyl-5-methyl-3,4,5,6a,7,8,9,9a-octahydrocyclopent[4,5]-imidazo[2,1-b]purin-4-one; 3-acetyl-1-(2-chlorobenzyl)-2-propylindole-6-carboxylate; 3-acetyl-1-(2-chlorobenzyl)-2-propylindole-6-carboxylate; 4-bromo-5-(3-pyridylmethylamino)-6-(3-(4-chlorophenyl) propoxy)-3-(2H)pyridazinone; 1-methyl-5(5-morpholinoacetyl-2-n-propoxyphenyl)-3-n-propyl-20 1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidin-7-one; 1-[4-[(1,3-benzodioxol-5-ylmethyl)arnino]-6-chloro-2-quinazolinyl]-4-piperidinecarboxylic acid, monosodium salt; Pharmaprojects No. 4516 (Glaxo Wellcome); Pharmaprojects No. 5051 (Bayer); Pharmaprojects No. 5064 (Kyowa Hakko; see WO 96/26940); Pharmaprojects No. 5069 (Schering Plough); GF-196960 (Glaxo Wellcome); E-25 8010 and E-4010 (Eisai); Bay-38-3045 & 38-9456 (Bayer) and Sch-51866.

It is to be understood that the contents of the above published patent applications, and in particular the general formulae of the therapeutically active compounds of the claims and the exemplified compounds therein are incorporated herein in their entirety by reference thereto.

30

The suitability of any particular cGMP PDE5 inhibitor can be readily determined by evaluation of its potency and selectivity using literature methods followed by evaluation of its toxicity, absorption, metabolism, pharmacokinetics, etc in

accordance with standard pharmaceutical practice.

Preferably, the cGMP PDE5 inhibitors have an IC_{50} against the PDE5 enzyme of less than 100 nanomolar (preferably, at less than 50 nanomolar).

5

According to a further aspect the present invention provides for the use of a selective pyrazolopyrimidinone cGMP PDE5 inhibitor or a pharmaceutical composition thereof in the preparation of a medicament for the curative, palliative or prophylactic treatment of type 2 diabetes mellitus or IGT in a mammal wherein

10 the selective cGMP PDE5 inhibitor is selected from : sildenafil, 5-(2-ethoxy-5-morpholinoacetylphenyl)-1-ethyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-*d*]pyrimidin-7-one, 3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-n-propoxyphenyl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-*d*]pyrimidin-7-one, 3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-

15 2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-*d*]pyrimidin-7-one, 5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-2,6-dihydro-7H-pyrazolo[4,3-*d*]pyrimidin-7-one and 1-[[3-(3,4-dihydro-5-methyl-4-oxo-7-propylimidazolo[5,1-*f*]-as-triazin-2-yl)-4-ethoxyphenyl]sulphonyl]-4-ethylpiperazine or a pharmaceutically acceptable salt, solvate, pro-drug or polymorph thereof.

20

More particularly, the present invention provides a method of treating a patient with type 2 diabetes mellitus, IGT or IR which comprises treating the patient with an effective amount of a selective pyrazolopyrimidinone cGMP PDE5 inhibitor selected from sildenafil, 5-(5-Acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidiny)-2,6-dihydro-7H-pyrazolo[4,3-*d*]pyrimidin-7-one or 5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-2,6-

25 dihydro-7H-pyrazolo[4,3-*d*]pyrimidin-7-one or pharmaceutically acceptable salts, solvates, pro-drugs, polymorphs or pharmaceutical compositions thereof.

30

According to a further aspect still the invention also provides for the use of a selective pyrazolopyrimidinone cGMP PDE5 inhibitor and in particular sildenafil, 5-(5-Acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidiny)-2,6-dihydro-7H-pyrazolo[4,3-*d*]pyrimidin-7-one or 5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-1-(2-methoxyethyl)-1,6-dihydro-7H-pyrazolo[4,3-

d]pyrimidin-7-one for the manufacture of a composition for the treatment or prophylaxis of type 2 diabetes mellitus, IGT or IR.

According to a further aspect the present invention additionally provides for
5 the use of sildenafil or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof for the treatment of type 2 diabetes mellitus, IGT or IR.

IC₅₀ values for the cGMP PDE5 inhibitors may be determined using the PDE5
10 assay in the Test Methods Section hereinafter.

Preferably the cGMP PDE5 inhibitors used in the pharmaceutical compositions according to the present invention are selective for the PDE5 enzyme. Preferably they have a selectivity of PDE5 over PDE3 of greater than 100 more preferably
15 greater than 300. More preferably the PDE5 has a selectivity over both PDE3 and PDE4 of greater than 100, more preferably greater than 300.

Selectivity ratios may readily be determined by the skilled person. IC₅₀ values for the PDE3 and PDE4 enzyme may be determined using established literature
20 methodology, see S A Ballard *et al*, Journal of Urology, 1998, vol. 159, pages 2164-2171 and as detailed herein after.

According to a further aspect, the invention provides the use of a pharmaceutical medicament for use according to any aspect of the invention
25 hereinbefore or hereinafter detailed which is adapted for administration by mouth, said medicament comprising a PDE5 inhibitor having and IC₅₀ of less than 100 nanomolar and a selectivity over PDE3 of greater than 100. Wherein said oral use is for the treatment of the insulin resistance syndrome, or type 2 diabetes mellitus or IGT or IR according to any aspect of the invention detailed herein
30 before preferably said PDE5 inhibitor is a pyrazolopyrimidinone, more preferably sildenafil, 5-(2-ethoxy-5-morpholinoacetylphenyl)-1-ethyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, 3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-n-propoxyphenyl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, 3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-

2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-*d*]pyrimidin-7-one, 5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-2,6-dihydro-7H-pyrazolo[4,3-*d*]pyrimidin-7-one and 1-[[3-(3,4-dihydro-5-methyl-4-oxo-7-propylimidazolo[5,1-*f*]-as-trizin-2-yl)-4-ethoxyphenyl]sulphonyl]-4-ethylpiperazine
 5 or a pharmaceutically acceptable salt, solvate, pro-drug or polymorph thereof, and in particular sildenafil, 5-(5-Acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidiny)-2,6-dihydro-7H-pyrazolo[4,3-*d*]pyrimidin-7-one or 5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-1-(2-methoxyethyl)-1,6-dihydro-7H-pyrazolo[4,3-*d*]pyrimidin-7-one, and especially sildenafil.

10

Wherein said oral administration of a PDE5 inhibitor is for the treatment of insulin resistance; type 2 diabetes mellitus; impaired glucose tolerance (IGT); dislipidemia; hyperuricemia and/or gout; or a procoagulant state then said PDE5
 15 inhibitor is a pyrazolopyrimidinone, more preferably sildenafil, 5-(2-ethoxy-5-morpholinoacetylphenyl)-1-ethyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-*d*]pyrimidin-7-one, 3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-n-propoxyphenyl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-*d*]pyrimidin-7-one, 3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-
 20 2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-*d*]pyrimidin-7-one, 5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-2,6-dihydro-7H-pyrazolo[4,3-*d*]pyrimidin-7-one and 1-[[3-(3,4-dihydro-5-methyl-4-oxo-7-propylimidazolo[5,1-*f*]-as-trizin-2-yl)-4-ethoxyphenyl]sulphonyl]-4-ethylpiperazine or a pharmaceutically acceptable salt, solvate, pro-drug or polymorph thereof, and
 25 in particular sildenafil, 5-(5-Acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidiny)-2,6-dihydro-7H-pyrazolo[4,3-*d*]pyrimidin-7-one or 5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-1-(2-methoxyethyl)-1,6-dihydro-7H-pyrazolo[4,3-*d*]pyrimidin-7-one, and especially sildenafil.

30 As proposed hereinbefore amplification of the cGMP signal, using cGMP specific PDE5 inhibitors in patients with the Insulin Resistance Syndrome would help to optimise the insulin glucose uptake signal and improve insulin action at key tissues. By making tissues more sensitive to insulin, it is thereby also proposed

herein that improvements in the clinical parameters of the IRS would result. Thus, according to a further aspect the present invention additionally provides a method for improving insulin action (treating insulin resistance) wherein said method comprises treating a patient with the insulin resistance syndrome which comprises
5 treating a patient with underlying insulin resistance with an effective amount of a selective pyrazolopyrimidinone cGMP PDE5 inhibitor (as detailed hereinbefore).

Thus the present invention additionally provides a method for treating insulin resistance which comprises treating a patient with underlying insulin resistance
10 with an effective amount of a selective pyrazolopyrimidinone cGMP PDE5 inhibitor selected from sildenafil, 5-(5-Acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidiny)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one or 5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one or pharmaceutically acceptable salts, solvates,
15 pro-drugs, polymorphs or pharmaceutical compositions thereof.

Depending on the individual with IRS, any of the methods detailed hereinbefore may have a beneficial effect on one or more of conditions associated with the IRS as defined herein. Thus according to a further aspect the present
20 invention additionally provides a method of treating type 2 diabetes mellitus or impaired glucose tolerance (IGT); or dyslipidemia, or hyperuricemia, or the procoagulant state wherein said method comprises treating a patient with underlying insulin resistance with an effective amount of a selective pyrazolopyrimidinone cGMP PDE5 inhibitor (as detailed hereinbefore).

25

Thus the present invention additionally provides a method for treating type 2 diabetes mellitus or impaired glucose tolerance (IGT); or dyslipidemia, or hyperuricemia, or the procoagulant state which comprises treating a patient with an effective amount of a selective pyrazolopyrimidinone cGMP PDE5 inhibitor
30 selected from sildenafil, 5-(5-Acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidiny)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one or 5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one or pharmaceutically acceptable salts, solvates, pro-drugs, polymorphs or pharmaceutical compositions thereof.

The pharmaceutically acceptable salts of the selective cGMP PDE5 inhibitor compounds as disclosed herein for use in the treatment of the insulin resistance syndrome in accordance with the present invention which contain a
5 basic centre are, for example, non-toxic acid addition salts formed with inorganic acids such as hydrochloric, hydrobromic, hydroiodic, sulphuric and phosphoric acid, with carboxylic acids or with organo-sulphonic acids. Examples include the HCl, HBr, HI, sulphate or bisulphate, nitrate, phosphate or hydrogen phosphate, acetate, benzoate, succinate, saccharate, fumarate, maleate, lactate, citrate,
10 tartrate, gluconate, camsylate, methanesulphonate, ethanesulphonate, benzene-sulphonate, p-toluenesulphonate and pamoate salts. The selective cGMP PDE5 inhibitor compounds for use in the present invention can also provide pharmaceutically acceptable metal salts, in particular non-toxic alkali and alkaline earth metal salts, with bases. Examples include the sodium, potassium,
15 aluminium, calcium, magnesium, zinc and diethanolamine salts. For a review on suitable pharmaceutical salts see Berge *et al*, J. Pharm, Sci., 66, 1-19, 1977.

The cGMP PDE5i compounds suitable for use in accordance with any aspect of the present invention as disclosed herein, their pharmaceutically
20 acceptable salts, and pharmaceutically acceptable solvates of either entity can be administered alone but, in human therapy will generally be administered in admixture with a suitable pharmaceutical excipient diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical practice.

25

For example, the cGMP PDE5i compounds suitable for use in accordance with the present invention or salts or solvates thereof can be administered orally, buccally or sublingually in the form of tablets, capsules (including soft gel capsules), multi-particulate, gels, films, ovules, elixirs, solutions or suspensions,
30 which may contain flavouring or colouring agents, for immediate-, delayed-, modified-, sustained-, dual-, controlled-release or pulsatile delivery applications. Such compounds may also be administered via fast dispersing or fast dissolving dosages forms or in the form of a high energy dispersion or as coated particles. Suitable pharmaceutical formulations may be in coated or un-coated form as

desired.

Such solid pharmaceutical compositions, for example, tablets may contain excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate, glycine and starch (preferably corn, potato or tapioca starch), disintegrants such as sodium starch glycolate, croscarmellose sodium and certain complex silicates, and granulation binders such as polyvinylpyrrolidone, hydroxypropylmethyl cellulose (HPMC), hydroxypropylcellulose (HPC), sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, stearic acid, glyceryl behenate and talc may be included.

Solid compositions of a similar type may also be employed as fillers in gelatin capsules or HPMC capsules. Preferred excipients in this regard include lactose, starch, a cellulose, milk sugar or high molecular weight polyethylene glycols. For aqueous suspensions and/or elixirs, the cGMP PDE5i compounds may be combined with various sweetening or flavouring agents, colouring matter or dyes, with emulsifying and/or suspending agents and with diluents such as water, ethanol, propylene glycol and glycerin, and combinations thereof.

20

Modified release and pulsatile release dosage forms may contain excipients such as those detailed for immediate release dosage forms together with additional excipients that act as release rate modifiers, these being coated on and/or included in the body of the device. Release rate modifiers include, but are not exclusively limited to, hydroxypropylmethyl cellulose, methyl cellulose, sodium carboxymethylcellulose, ethyl cellulose, cellulose acetate, polyethylene oxide, Xanthan gum, Carbomer, ammonio methacrylate copolymer, hydrogenated castor oil, carnauba wax, paraffin wax, cellulose acetate phthalate, hydroxypropylmethyl cellulose phthalate, methacrylic acid copolymer and mixtures thereof. Modified release and pulsatile release dosage forms may contain one or a combination of release rate modifying excipients. Release rate modifying excipients may be present both within the dosage form i.e. within the matrix, and/or on the dosage form i.e. upon the surface or coating.

Fast dispersing or dissolving dosage formulations (FDDFs) may contain the following ingredients: aspartame, acesulfame potassium, citric acid, croscarmellose sodium, crospovidone, diascorbic acid, ethyl acrylate, ethyl cellulose, gelatin, hydroxypropylmethyl cellulose, magnesium stearate, mannitol, methyl methacrylate, mint flavouring, polyethylene glycol, fumed silica, silicon dioxide, sodium starch glycolate, sodium stearyl fumarate, sorbitol, xylitol. The terms dispersing or dissolving as used herein to describe FDDFs are dependent upon the solubility of the drug substance used i.e. where the drug substance is insoluble a fast dispersing dosage form can be prepared and where the drug substance is soluble a fast dissolving dosage form can be prepared.

The cGMP PDE5i compounds suitable for use in accordance with the present invention can also be administered parenterally, for example, intracavernosally, intravenously, intra-arterially, intraperitoneally, intrathecally, intraventricularly, intraurethrally intrasternally, intracranially, intramuscularly or subcutaneously, or they may be administered by infusion or needle-free techniques. For such parenteral administration they are best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood. The aqueous solutions should be suitably buffered (preferably to a pH of from 3 to 9), if necessary. The preparation of suitable parenteral formulations under sterile conditions is readily accomplished by standard pharmaceutical techniques well-known to those skilled in the art.

For oral and parenteral administration to human patients, the daily dosage level of the selective cGMP PDE5 inhibitor compounds for use according to any aspect of the present invention as disclosed herein or salts or solvates thereof will usually be from 5 to 500 mg (in single or divided doses). For the treatment of the Insulin Resistance Syndrome the dosage may be via single dose, divided daily dose, multiple daily dose, acute dosing, continuous (chronic) daily dosing for a specified period which may be from one to five or 5 or more, such as up to 10 or more days. Alternatively the treatment of the Insulin Resistance Syndrome may be affected by continuous dosing, such as for example, via a controlled release dosage form wherein such continuous dosage form can be administered on a

daily basis for a number of days or wherein such continuous dosing can be affected via a slow-release formulation which doses for more than one day at a time. For chronic conditions treatment may be effected via continuous daily dosing or via repeated regular dosing of controlled or sustained release
5 formulation or such like. All references to the form of treatment may be equally applied to further aspects of the present invention as described herein such as for the treatment of type 2 diabetes mellitus, IGT or insulin resistance.

Thus, for example, tablets or capsules of the cGMP PDE5i compounds
10 suitable for use in accordance with the present invention or salts or solvates thereof may contain from 5 mg to 250 mg of active compound for administration singly or two or more at a time, as appropriate. The physician in any event will determine the actual dosage which will be most suitable for any individual patient and it will vary with the age, weight and response of the particular patient. The
15 above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited and such are within the scope of this invention.

Example Tablet Formulation

20 In general a tablet formulation could typically contain between about 0.01mg and 500mg of selective cGMP PDE5 inhibitor compounds for use in accordance with the present invention (or a salt thereof) whilst tablet fill weights may range from 50mg to 1000mg. An example formulation for a 10mg tablet is illustrated:

25

Formulation 1

<u>Ingredient</u>	<u>%w/w</u>
Sildenafil citrate	10.000*
Lactose	64.125
30 Starch	21.375
Croscarmellose Sodium	3.000
Magnesium Stearate	1.500

* This quantity is typically adjusted in accordance with drug activity.

Formulation 2

A tablet is prepared using the following ingredients :

5		<u>Quantity (mg/tablet)</u>
	sildenafil	250
	cellulose, microcrystalline	400
	silicon dioxide, fumed	10
	stearic acid	5
10	total	<u>665mg</u>

the components are blended and compressed to form tablets each weighing 665mg.

15 Formulation 3

An intravenous formulation may be prepared as follows:

sildenafil	100mg
isotonic saline	1,000ml

20

The cGMP PDE5i compounds suitable for use in accordance with the present invention can also be administered intranasally or by inhalation and are conveniently delivered in the form of a dry powder inhaler or an aerosol spray presentation from a pressurised container, pump, spray or nebuliser with the use of a suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, a hydrofluoroalkane such as 1,1,1,2-tetrafluoroethane (HFA 134A [trade mark] or 1,1,1,2,3,3,3-heptafluoropropane (HFA 227EA [trade mark]), carbon dioxide or other suitable gas. In the case of a pressurised aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. The pressurised container, pump, spray or nebuliser may contain a solution or suspension of the active compound, e.g. using a mixture of ethanol and the propellant as the solvent, which may additionally contain a lubricant, e.g. sorbitan trioleate. Capsules and cartridges (made, for example, from gelatin) for

use in an inhaler or insufflator may be formulated to contain a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.

Aerosol or dry powder formulations are preferably arranged so that each
5 metered dose or "puff" contains from 1 to 50 mg of a compound of the invention for delivery to the patient. The overall daily dose with an aerosol will be in the range of from 1 to 50 mg which may be administered in a single dose or, more usually, in divided doses throughout the day.

10 The cGMP PDE5i compounds suitable for use in accordance with the present invention may also be formulated for delivery via an atomiser. Formulations for atomiser devices may contain the following ingredients as solubilisers, emulsifiers or suspending agents: water, ethanol, glycerol, propylene glycol, low molecular weight polyethylene glycols, sodium chloride, fluorocarbons,
15 polyethylene glycol ethers, sorbitan trioleate, oleic acid.

Alternatively, the cGMP PDE5i compounds suitable for use in accordance with the present invention or salts or solvates thereof can be administered in the form of a suppository or pessary, or they may be applied topically in the form of a
20 gel, hydrogel, lotion, solution, cream, ointment or dusting powder. The cGMP PDE5i compounds suitable for use in accordance with the present invention or salts or solvates thereof may also be dermally or transdermally administered, for example, by the use of a skin patch. They may also be administered by the pulmonary or rectal routes.

25

The compounds may also be administered by the ocular route. For ophthalmic use, the compounds can be formulated as micronised suspensions in isotonic, pH adjusted, sterile saline, or, preferably, as solutions in isotonic, pH adjusted, sterile saline, optionally in combination with a preservative such as a
30 benzylalkonium chloride. Alternatively, they may be formulated in an ointment such as petrolatum.

For application topically to the skin, the cGMP PDE5i compounds suitable for use in accordance with the present invention or salts or solvates thereof can be

formulated as a suitable ointment containing the active compound suspended or dissolved in, for example, a mixture with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water. Alternatively, they can
5 be formulated as a suitable lotion or cream, suspended or dissolved in, for example, a mixture of one or more of the following: mineral oil, sorbitan monostearate, a polyethylene glycol, liquid paraffin, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

10 The cGMP PDE5i compounds suitable for use in accordance with the present invention may also be used in combination with a cyclodextrin. Cyclodextrins are known to form inclusion and non-inclusion complexes with drug molecules. Formation of a drug-cyclodextrin complex may modify the solubility, dissolution rate, bioavailability and/or stability property of a drug molecule. Drug-
15 cyclodextrin complexes are generally useful for most dosage forms and administration routes. As an alternative to direct complexation with the drug the cyclodextrin may be used as an auxiliary additive, e.g. as a carrier, diluent or solubiliser. Alpha-, beta- and gamma-cyclodextrins are most commonly used and suitable examples are described in WO-A-91/11172, WO-A-94/02518 and WO-A-
20 98/55148.

Generally, in humans, oral administration is the preferred route, being the most convenient. In circumstances where the recipient suffers from a swallowing disorder or from impairment of drug absorption after oral administration, the drug
25 may be administered parenterally, sublingually or buccally.

For veterinary use, a compound, or a veterinarily acceptable salt thereof, or a veterinarily acceptable solvate or pro-drug thereof, is administered as a suitably acceptable formulation in accordance with normal veterinary practice and the
30 veterinary surgeon will determine the dosing regimen and route of administration which will be most appropriate for a particular animal.

Thus, for example, tablets or capsules of selective cGMP PDE5 inhibitor compounds for use in accordance with the invention or salts or solvates thereof

may contain from 5 mg to 250 mg of active compound for administration singly or two or more at a time, as appropriate. The physician in any event will determine the actual dosage which will be most suitable for any individual patient and it will vary with the age, weight and response of the particular patient. The above
5 dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited and such are within the scope of this invention.

It is to be appreciated that all references herein to treatment include
10 curative, palliative and prophylactic treatment and include acute treatment (taken as required) and chronic treatment (i.e. longer term continuous treatment).

The present invention additionally comprises treatment of the insulin resistance syndrome with a combination of a cGMP PDE₅ inhibitor compound as
15 defined herein with one or more additional pharmaceutically active agents such as:

- 1) one or more naturally occurring or synthetic prostaglandins or esters thereof. Suitable prostaglandins for use herein include compounds such as
20 alprostadil, prostaglandin E₁, prostaglandin E₀, 13, 14 - dihydroprosta glandin E₁, prostaglandin E₂, eprostinol, natural synthetic and semi-synthetic prostaglandins and derivatives thereof including those described in WO-00033825 and/or US 6,037,346 issued on 14th March 2000 all incorporated herein by reference, PGE₀, PGE₁, PGA₁, PGB₁, PGF₁ α , 19-hydroxy PGA₁, 19-
25 hydroxy - PGB₁, PGE₂, PGB₂, 19-hydroxy-PGA₂, 19-hydroxy-PGB₂, PGE₃ α , carboprost tromethamine dinoprost, tromethamine, dinoprostone, lipo prost, gemeprost, metenoprost, sulprostune, tiaprost and moxisylate; and/or
- 2) one or more α - adrenergic receptor antagonist compounds, α -blockers.
30 Suitable compounds for use herein include: the α -adrenergic receptor blockers as described in PCT application WO99/30697 published on 14th June 1998, the disclosures of which relating to α -adrenergic receptors are incorporated herein by reference and include, selective α_1 -adrenoceptor or α_2 -adrenoceptor

blockers and non-selective adrenoceptor blockers, suitable α_1 -adrenoceptor blockers include: phentolamine, phentolamine mesylate, trazodone, alfuzosin, indoramin, naftopidil, tamsulosin, dapiprazole, phenoxybenzamine, idazoxan, efaraxan, yohimbine (α_2 -blocker), rauwolfia alkaloids, Recordati 15/2739, SNAP 1069, SNAP 5089, RS17053, SL 89.0591, doxazosin, terazosin, abanoquil and prazosin; α_2 -blocker blockers from US 6,037,346 [14th March 2000] dibenarnine, tolazoline, trimazosin and dibenarnine; α -adrenergic receptors as described in US patents: 4,188,390; 4,026,894; 3,511,836; 4,315,007; 3,527,761; 3,997,666; 2,503,059; 4,703,063; 3,381,009; 4,252,721 and 2,599,000 each of which is incorporated herein by reference; α_2 -Adrenoceptor blockers include: clonidine, papaverine, papaverine hydrochloride, optionally in the presence of a cardiotonic agent such as pirxamine; and/or

3) one or more NO-donor (NO-agonist) compounds. Suitable NO-donor compounds for use herein include organic nitrates, such as mono- di or tri-nitrates or organic nitrate esters including glyceryl trinitrate (also known as nitroglycerin), isosorbide 5-mononitrate, isosorbide dinitrate, pentaerythritol tetranitrate, erythrityl tetranitrate, sodium nitroprusside (SNP), 3-morpholiniosydnonimine molsidomine, S-nitroso- N-acetyl penicilliamine (SNAP) S-nitroso-N-glutathione (SNO-GLU), N-hydroxy - L-arginine, amylnitrate, linsidomine, linsidomine chlorohydrate, (SIN-1) S-nitroso - N-cysteine, diazenium diolates, (NONOates), 1,5-pentanedinitrate, L-arginine, ginseng, zizphi fructus, molsidomine, Re - 2047, nitrosylated maxisylyte derivatives such as NMI-678-11 and NMI-937 as described in published PCT application WO 0012075 ; and/or

4) one or more potassium channel openers or modulators. Suitable potassium channel openers/modulators for use herein include nicorandil, cromokalim, levromakalim, lemakalim, pinacidil, cliazoxide, minoxidil, charybdotoxin, glyburide, 4-amini pyridine, BaCl_2 ; and/or

5) one or more dopaminergic agents, preferably apomorphine or a selective D2, D3 or D2/D3 agonist such as, pramipexole and ropirinol (as claimed in WO-

0023056), L-Dopa or carbidopa, PNU95666 (as claimed in WO-0040226); and/or


- 6) one or more vasodilator agents. Suitable vasodilator agents for use herein include nimodipine, pinacidil, cycloandelate, isoxsuprine, chloroprumazine, halo peridol, Rec 15/2739, trazodone, and/or
- 7) one or more thromboxane A2 agonists; and/or
- 8) one or more ergot alkaloids; Suitable ergot alkaloids are described in US patent 6,037,346 issued on 14th March 2000 and include acetergamine, brazergoline, bromerguride, cianergoline, delorgotril, disulergine, ergonovine maleate, ergotamine tartrate, etisulergine, lergotril, lysergide, mesulergine, metergoline, metergotamine, nicergoline, pergolide, propisergide, proterguride, terguride; and/or
- 9) one or more compounds which modulate the action of natriuretic factors in particular atrial natriuretic factor (also known as atrial natriuretic peptide), B type and C type natriuretic factors such as inhibitors of neutral endopeptidase; and/or
- 10) one or more angiotensin receptor antagonists such as losartan; and/or
- 11) one or more substrates for NO-synthase, such as L-arginine; and/or
- 12) one or more calcium channel blockers such as amlodipine; and/or
- 13) one or more antagonists of endothelin receptors and inhibitors of endothelin-converting enzyme; and/or
- 14) one or more cholesterol lowering agents such as statins (e.g. atorvastatin/ Lipitor- trade mark) and fibrates; and/or
- 15) one or more antiplatelet and antithrombotic agents, e.g. tPA, uPA, warfarin, hirudin and other thrombin inhibitors, heparin, thromboplastin activating factor

inhibitors; and/or

16) one or more insulin sensitising agents such as Rezulin, Avandia or Actos and hypoglycaemic agents such as, but not limited to, glipizide (sulfonylureas),
5 metformin, or acarbose; and/or

17) one or more acetylcholinesterase inhibitors such as donezipil; and/or

18) one or more estrogen receptor modulators and/or estrogen agonists and/or
10 estrogen antagonists, preferably raloxifene or lasofoxifene, (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydronaphthalene-2-ol and pharmaceutically acceptable salts thereof (compound A below) the preparation of which is detailed in WO 96/21656.



Compound A

20 23) one or more of a further PDE inhibitor, more particularly a PDE 2, 4, 7 or 8 inhibitor, preferably a PDE2 inhibitor said inhibitors preferably having an IC₅₀ against the respective enzyme of less than 100nM: and/or

24) one or more of an NPY (neuropeptide Y) inhibitor, more particularly NPY1 or NPY5 inhibitor, preferably NPY1 inhibitor, preferably said NPY inhibitors (including NPY Y1 and NPY Y5) having an IC₅₀ of less than 100nM , more preferably less
5 than 50nM, suitable NPY and in particular NPY1 inhibitor compounds are described in EP-A-1097718; and/or

25) one or more of vasoactive intestinal peptide (VIP), VIP mimetic, more particularly mediated by one or more of the VIP receptor subtypes VPAC1,VPAC
10 or PACAP (pituitary adenylate cyclase activating peptide), one or more of a VIP receptor agonist or a VIP analogue (eg Ro-125-1553) or a VIP fragment, one or more of a α -adrenoceptor antagonist with VIP combination (eg Invicorp, Aviptadil); and/or

15 26) one or more of a melanocortin receptor agonist or modulator or melanocortin enhancer, such as melanotan II, PT-14, PT-141 or compounds claimed in WO-09964002, WO-00074679, WO-09955679, WO-00105401, WO-00058361, WO-00114879, WO-00113112, WO-09954358 and/or

20 27) one or more of a serotonin receptor agonist, antagonist or modulator, more particularly agonists, antagonists or modulators for 5HT_{1A} (including VML 670), 5HT_{2A}, 5HT_{2C}, 5HT₃ and/or 5HT₆ receptors, including those described in WO-09902159, WO-00002550 and/or WO-00028993; and/or

25 28) one or more of a testosterone replacement agent (inc dehydroandrostendione), testosterone (Tostrelle), dihydrotestosterone or a testosterone implant; and/or

29) one or more of estrogen, estrogen and medroxyprogesterone or
30 medroxyprogesterone acetate (MPA) (i.e. as a combination), or estrogen and methyl testosterone hormone replacement therapy agent (e.g. HRT especially Premarin, Cenestin, Oestrofeminal, Equin, Estrace, Estrofem, Elleste Solo, Estring, Estraderm TTS, Estraderm Matrix, Dermestril, Premphase, Preempro, Prempak, Premique, Estratest, Estratest HS, Tibolone); and /or

- 30) one or more of a modulator of transporters for noradrenaline, dopamine and/or serotonin, such as bupropion, GW-320659
- 5 31) one or more of a purinergic receptor agonist and/or modulator; and/or
- 32) one or more of a neurokinin (NK) receptor antagonist, including those described in WO-09964008; and/or
- 10 33) one or more of an opioid receptor agonist, antagonist or modulator, preferably agonists for the ORL-1 receptor and/or;
- 34) one or more of an agonist or modulator for oxytocin/vasopressin receptors, preferably a selective oxytocin agonist or modulator and/or;
- 15 35) one or more modulators of cannabinoid receptors.
- 36) one or more CNS active agents; and/or
- 20 37) one or more compounds which inhibit angiotensin-converting enzyme such as enapril, and one or more combined inhibitors of angiotensin-converting enzyme and neutral endopeptidase such as omapatrilat; and/or
- 38) L-DOPA or carbidopa; and/or
- 25 39) one or more steroidal or non-steroidal anti-inflammatory agents; and/or
- 40) one or more protein kinase C- β inhibitors such as LY333531; and/or
- 30 41) one or more activators of AMP-activated protein kinase such as 5-amino-4-imidazolecarboxamide ribonucleoside; and/or
- 42) insulin; and/or

43) weight loss agents such as sibutramine or orlistat; and/or

44) one or more dipeptidyl peptidase IV inhibitors such as NVP DPP728 or
5 P32/98; and/or

45) one or more glucagon antagonists such as NNC25-2504

46) one or more agents that inhibit PTP1B such as PTP112; and/or
10

47) one or more agents that reduce PTP1B levels using antisense technology;
and/or

48) one or more glycogen synthase kinase-3 inhibitors such as Chir98014; and/or
15

49) one or more GLP-1 agonists such as GLP1, NN-2211 or exendin 4; and/or

50) one or more PPAR-gamma agonists such as Rezulin, Avandia, Actos or
CS011; and/or,
20

51) one or more PPAR-alpha agonists such as fenofibrate; and/or

52) one or more dual PPAR-alpha/PPAR-gamma agonists such as farglitazar,
rosiglitazone, pioglitazone, GW1929, DRF2725, AZ242 or KRP 297, and/or
25

53) one or more sorbitol dehydrogenase inhibitors such as CP-470711; and/or

54) one or more aldose reductase inhibitors such as zopolrestat, zenarestat, or
fidarestat.
30

55) one or more preparations of growth hormone or growth hormone
secretagogues; and/or

56) one or more of an NEP inhibitor, preferably wherein said NEP is EC 3.4.24.11

and more preferably wherein said NEP inhibitor is a selective inhibitor for EC 3.4.24.11, more preferably a selective NEP inhibitor is a selective inhibitor for EC 3.4.24.11, which has an IC_{50} of less than 100nM (e.g. omapatrilat, sampatrilat) suitable NEP inhibitor compounds are described in EP-A-1097719
 5 and/or;

According to a still further aspect the present invention comprises treatment of type 2 diabetes mellitus or IGT or IR with a combination of a cGMP PDE5 inhibitor compound which is a pyrazolopyrimidinone, more preferably sildenafil, 5-(2-ethoxy-5-morpholinoacetylphenyl)-1-ethyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-*d*]pyrimidin-7-one,
 10 3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-n-propoxyphenyl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-*d*]pyrimidin-7-one, 3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-*d*]pyrimidin-7-one, 5-[2-ethoxy-
 15 5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-2,6-dihydro-7H-pyrazolo[4,3-*d*]pyrimidin-7-one, 1-[[3-(3,4-dihydro-5-methyl-4-oxo-7-propylimidazolo[5,1-*f*]-as-triazin-2-yl)-4-ethoxyphenyl]sulphonyl]-4-ethylpiperzine or a pharmaceutically acceptable salt, solvate, pro-drug or polymorph thereof, and in particular sildenafil, 5-(5-Acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidiny)-2,6-dihydro-7H-pyrazolo[4,3-*d*]pyrimidin-7-one or 5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-1-(2-methoxyethyl)-1,6-dihydro-
 20 7H-pyrazolo[4,3-*d*]pyrimidin-7-one, and especially sildenafil with one or more additional pharmaceutically active agents wherein said additional agent comprises one or more agent from (1) to (56) as defined herein before.

25

Preferred combinations for use according to any of the aspects of the present invention as described herein include a combination of a cGMP PDE5i, and in particular sildenafil with one or more additional agents selected from (16), (40), (41), (42), (43), (50), (51), (52), (53) or (54) as detailed hereinbefore.

30

PHARMACOKINETICS
BIOAVAILABILITY

Preferably, the PDE5 inhibitor compounds for use in the present invention (and combinations) are orally bioavailable. Oral bioavailability refers to the proportion of an orally administered drug that reaches the systemic circulation. The factors that determine oral bioavailability of a drug are dissolution, membrane permeability and metabolic stability. Typically, a screening cascade of firstly *in vitro* and then *in vivo* techniques is used to determine oral bioavailability.

10

Dissolution, the solubilisation of the drug by the aqueous contents of the gastrointestinal tract (GIT), can be predicted from *in vitro* solubility experiments conducted at appropriate pH to mimic the GIT. Preferably the PDE5 inhibitor compounds for use according to the present invention have a minimum solubility of 50 mcg/ml. Solubility can be determined by standard procedures known in the art such as described in Adv. Drug Deliv. Rev. 23, 3-25, 1997.

Membrane permeability refers to the passage of the compound through the cells of the GIT. Lipophilicity is a key property in predicting this and is defined by *in vitro* Log $D_{7.4}$ measurements using organic solvents and buffer. Preferably the compounds of the invention have a Log $D_{7.4}$ of -2 to +4, more preferably -1 to +3. The log D can be determined by standard procedures known in the art such as described in J. Pharm. Pharmacol. 1990, 42:144.

Cell monolayer assays such as Caco-2 add substantially to prediction of favourable membrane permeability in the presence of efflux transporters such as p-glycoprotein, so-called Caco-2 flux. Preferably, compounds for use according to the present invention have a Caco-2 flux of greater than $2 \times 10^{-6} \text{cms}^{-1}$, more preferably greater than $5 \times 10^{-6} \text{cms}^{-1}$. The Caco-2 flux value can be determined by standard procedures known in the art such as described in J. Pharm. Sci, 1990, 79, 595-600

Metabolic stability addresses the ability of the GIT or the liver to metabolise compounds during the absorption process: the first pass effect. Assay systems

such as microsomes, hepatocytes etc are predictive of metabolic liability. Preferably the compounds of the Examples show metabolic stability in the assay system that is commensurate with an hepatic extraction of less than 0.5. Examples of assay systems and data manipulation are described in Curr. Opin.
5 Drug Disc. Devel., 201, 4, 36-44, Drug Met. Disp., 2000, 28, 1518-1523

Because of the interplay of the above processes further support that a drug will be orally bioavailable in humans can be gained by *in vivo* experiments in animals. Absolute bioavailability is determined in these studies by administering the
10 compound separately or in mixtures by the oral route. For absolute determinations (% absorbed) the intravenous route is also employed. Examples of the assessment of oral bioavailability in animals can be found in Drug Met. Disp., 2001, 29, 82-87; J. Med Chem, 1997, 40, 827-829, Drug Met. Disp., 1999, 27, 221-226. and as described in J. Pharm. Sci 79, 7, p595-600 (1990), and
15 Pharm. Res. vol 14, no. 6 (1997).

PDE5 inhibitor – TEST METHODS

Phosphodiesterase (PDE) inhibitory activity

Preferred PDE compounds suitable for use in accordance with the present
20 invention are potent and selective cGMP PDE5 inhibitors. *In vitro* PDE inhibitory activities against cyclic guanosine 3',5'-monophosphate (cGMP) and cyclic adenosine 3',5'-monophosphate (cAMP) phosphodiesterases can be determined by measurement of their IC₅₀ values (the concentration of compound required for 50% inhibition of enzyme activity).

25

The required PDE enzymes can be isolated from a variety of sources, including human corpus cavernosum, human and rabbit platelets, human cardiac ventricle, human skeletal muscle and bovine retina, essentially by the method of W.J. Thompson and M.M. Appleman (Biochem., 1971, 10, 311). In particular, the
30 cGMP-specific PDE (PDE5) and the cGMP-inhibited cAMP PDE (PDE3) can be obtained from human corpus cavernosum tissue, human platelets or rabbit platelets; the cGMP-stimulated PDE (PDE2) can be obtained from human corpus cavernosum; the calcium/calmodulin (Ca/CAM)-dependent PDE (PDE1) from human cardiac ventricle; the cAMP-specific PDE (PDE4) from human skeletal

muscle; and the photoreceptor PDE (PDE6) from bovine retina. Phosphodiesterases 7-11 can be generated from full length human recombinant clones transfected into SF9 cells.

- 5 Assays can be performed either using a modification of the "batch" method of W.J. Thompson *et al.* (Biochem., 1979, 18, 5228) or using a scintillation proximity assay for the direct detection of AMP/GMP using a modification of the protocol described by Amersham plc under product code TRKQ7090/7100. In summary, the effect of PDE inhibitors was investigated by assaying a fixed amount of
- 10 enzyme in the presence of varying inhibitor concentrations and low substrate, (cGMP or cAMP in a 3:1 ratio unlabelled to [³H]-labeled at a conc ~1/3 K_m) such that $IC_{50} \cong K_i$. The final assay volume was made up to 100 μ l with assay buffer [20 mM Tris-HCl pH 7.4, 5 mM MgCl₂, 1 mg/ml bovine serum albumin]. Reactions were initiated with enzyme, incubated for 30-60 min at 30°C to give <30%
- 15 substrate turnover and terminated with 50 μ l yttrium silicate SPA beads (containing 3 mM of the respective unlabelled cyclic nucleotide for PDEs 9 and 11). Plates were re-sealed and shaken for 20 min, after which the beads were allowed to settle for 30 min in the dark and then counted on a TopCount plate reader (Packard, Meriden, CT) Radioactivity units were converted to % activity of
- 20 an uninhibited control (100%), plotted against inhibitor concentration and inhibitor IC_{50} values obtained using the 'Fit Curve' Microsoft Excel extension.

Functional activity

- 25 This can be assessed in vitro by determining the capacity of a compound of the invention to enhance sodium nitroprusside-induced relaxation of pre-contracted rabbit corpus cavernosum tissue strips, as described by S.A. Ballard *et al.* (Brit. J. Pharmacol., 1996, 118 (suppl.), abstract 153P).

30 In vivo activity

Compounds were screened in anaesthetised dogs to determine their capacity, after i.v. administration, to enhance the pressure rises in the corpora cavernosa of the penis induced by intracavernosal injection of sodium nitroprusside, using a

method based on that described by Trigo-Rocha et al. (Neurourol. and Urodyn., 1994, 13, 71).

Effect of Specific Selective PDE5 inhibitors on Insulin Resistance Syndrome in
5 animals—Effects on Plasma Glucose and Serum Triglyceride Levels in *ob/ob* Mice

Biological Data

Experimental Protocol

Test Compounds:

10 The selective PDE5 inhibitor compounds to be tested were solubilized in 10% DMSO/0.1% pluronics and dosed via oral gavage using mouse oral feeding needles (20 gauge, Popper & Sons, Inc., New Hyde Park, NY). A volume of 4 ml/kg weight was administered for each dose. Compounds were tested at doses ranging from 1-50 mg/kg. Alternatively, the test selective PDE5 inhibitor
15 compound was administered in the drinking water and found to produce similar reductions in plasma glucose and triglycerides to the reductions observed for the same compound when administered by oral gavage.

20 Experimental Animals:

Male *ob/ob* mice obtained from Jackson Laboratories (Bar Harbor, ME) were used in the studies at 6 to 10 weeks of age. Mice were housed five per cage and allowed free access to D11 mouse chow (Purina, Brentwood, MO) and water.

25 Experimental Protocol:

Mice were allowed to acclimate to the Pfizer animal facilities for 1 week prior to the start of the study. On day one, retro-orbital blood samples were obtained and plasma glucose was determined as described hereinafter. Mice were then sorted into groups of five such that mean plasma glucose concentrations for each group
30 did not differ. On day one, mice were dosed with vehicle or a test selective PDE5 inhibitor compound only in the afternoon. Subsequently, mice were dosed twice a day on day 2-4 in the morning and in the afternoon. On day 5, the mice received an a.m. dose and bled 3 hours later for plasma preparation for glucose and triglyceride analysis as described below. Alternatively, test selective PDE5

inhibitor compound was administered in the drinking water commencing on the afternoon of day 1 and continuing through day 5, when mice were then bled for plasma preparation for glucose and triglyceride analysis as described below. Terminal plasma samples were collected on day 5 following the retro-orbital sinus
5 bleed as described below. Body weight was measured on days 1 and 5 of the study, and food consumption was assessed over the 5 day period.

Terminal Bleed and Tissue Collection:

10 On the morning of the last day of the study mice were dosed with test compound or vehicle at approximately 8:00 am. Three hours after dosing, 25 μ L of blood was obtained via the retro-orbital sinus and added to 100 μ L of 0.025 % heparinized-saline in Denville Scientific microtubes. The tubes were spun at the highest setting in a Beckman Microfuge 12 for 2 minutes. Plasma was collected
15 for plasma glucose and triglyceride determination. The mice were then sacrificed by decapitation and ~1 ml of blood was collected in Becton-Dickinson Microtainer brand plasma separator tubes with lithium heparin. The tubes were spun in a Beckman Microfuge 12 at the maximum setting for five minutes. Plasma was collected in 1.5 ml Eppendorf tubes and snap frozen in liquid nitrogen. Plasma
20 samples were stored at – 80° C until analyzed.

Metabolite and Hormone Analysis:

Plasma glucose and triglycerides were measured using the Alcyon Clinical Chemistry Analyzer (Abbott Laboratories, Abbott Park, IL) using kits supplied by
25 Abbott. Plasma cGMP was measured using the Biotrak enzyme-immunoassay system by Amersham (Piscataway, NJ). Via a similar technique the plasma insulin can be assessed by the Mercodia ELISA Insulin kit by ALPCO (Uppsala, Sweden). All assays were conducted according to instructions provided by the manufacturers.

30

Statistical Analysis:

Comparisons between drug treatments and appropriate vehicles were done by Student's t-test.

Results (summary):

Selective PDE5 inhibitors have been demonstrated to reduce the plasma glucose and serum triglyceride levels produced by ob/ob mice in accordance with the biological test methods detailed hereinbefore.

Results

Table 1 illustrates the changes in plasma glucose levels over a 5 day period observed with selective PDE5 inhibitor compounds.

Selective PDE5 Compound A: 3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-n-propoxyphenyl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

Selective PDE5 Compound B: 5-(2-ethoxy-5-morpholinoacetylphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

Table 1

	Changes in Plasma Glucose Concentrations (mg/dl)
Vehicle	-9 ± 22
PDE5 A – 10mg/kg	-115 ± 34*
PDE5 A – 50 mg/kg	-105 ± 25*
PDE5 B – 25 mg/kg	-97 ± 32*

The data in Table 1 are presented as mean ± standard error of the mean. These numbers reflect absolute decreases in plasma glucose levels. Significant differences from the Vehicle control are indicated as *p < 0.05.

Table 2 illustrates the change in plasma cGMP and plasma triglyceride levels in ob/ob mice observed with the test selective PDE5 inhibitor compounds A and B.

5

Table 2

	Plasma cGMP Level (mg/dl)	Plasma Triglyceride Level (mg/dl)
Vehicle	9.8 ± 0.5	178 ± 16
PDE5 A – 10mg/kg	$48.3 \pm 19.0^{\wedge}$	163 ± 10
PDE5 B – 25 mg/kg	$30.7 \pm 3.3^{**}$	$143 \pm 7^{\wedge}$

10 The data in Table 2 are presented as mean \pm standard error of the mean. Significant differences from the Vehicle control as indicated as $^{\wedge}p < 0.1$, $^{*}p < 0.05$, $^{**}p < 0.01$.

15 Table 3 illustrates the reduction in plasma glucose levels over a 5 day period observed with selective a PDE5 inhibitor compound administered in the drinking water of the mice.

Selective PDE5 Compound C: sildenafil

20

Table 3

	Changes in Plasma Glucose Concentrations (mg/dl)
Vehicle	25 ± 25
PDE5 C – 9 mg/kg	-27 ± 34
PDE5 C – 22 mg/kg	-15 ± 27
PDE5 C – 45 mg/kg	$-36 \pm 22^{\wedge}$

The data in Table 3 are presented as mean \pm standard error of the mean.

Positive values in this table reflect a decrease in plasma glucose level. Significant differences from the Vehicle control are indicated as $^{\wedge}p < 0.1$.

Table 4 illustrates the triglyceride levels in *ob/ob* mice treated with the test
5 selective PDE5 inhibitor compound C administered in the drinking water of the mice.

Table 4

	Plasma Triglyceride Level (mg/dl)
Vehicle	204 \pm 13
PDE5 C – 9 mg/kg	163 \pm 14*
PDE5 C – 22 mg/kg	212 \pm 20
PDE5 C – 45 mg/kg	151 \pm 10**

10 The data in Table 4 are presented as mean \pm standard error of the mean. Significant differences from the Vehicle control as indicated as * $p < 0.05$, ** $p < 0.01$.

15 Taken together, these experimental results in the hyperglycemic, insulin-resistant *ob/ob* mouse suggest that selective PDE5 inhibition improves metabolic parameters associated with IRS.

Further these results suggest that treatment with selective PDE5 inhibitors can
20 result in decreases in plasma glucose concentrations. As detailed herein before decreases in plasma glucose concentrations are consistent with an improvement in insulin resistance which is a clinical parameter of the IRS, and, as further detailed hereinbefore such improvements, in subjects with type 2 diabetes mellitus would manifest as improvements in for example haemoglobin A1c.

25

These results also suggest that treatment with selective PDE5 inhibitors can result in improvements in serum lipid levels. As detailed herein before an improvement

in serum lipid levels (such as in triglyceride levels) is consistent with an improvement in insulin resistance which is a clinical parameter of the IRS. Such improvements, in subjects with the IRS (as defined herein) would manifest as improvements in for example dyslipidemia (hypertriglyceridaemia).

5

These results in the hyperglycemic, insulin-resistant *ob/ob* mouse additionally suggest that continuous treatment with a selective PDE5 inhibitor can improve metabolic parameters associated with IRS in 5 days or less.

10 Clinical Trial Data 1

In a 28-day clinical trial with sildenafil, serum triglyceride levels were obtained before and at the end of dosing from non-diabetic subjects. Doses included in the study were 10mg, 25mg and 50gm of sildenafil or placebo, dosed once daily.

15 These subjects had the insulin resistance syndrome, as defined by the risk factors as defined hereinbefore. Data are presented in tables 5 and 6 below to illustrate that subjects had evidence of the insulin resistance syndrome.

Table 5 illustrates the sub-division of the IRS components amongst the subjects
20 studied.

Coronary artery disease (CAD) / ischaemic heart disease (IHD) is one clinical end-point in subjects having the Insulin Resistance Syndrome. For this reason the presence of CAD/IHD was taken as evidence to support the existence of the
25 Insulin Resistance Syndrome in patients with only one of the defined risk factors.

Table 5

30

IRS Component	Placebo	Sildenafil	Total
Dyslipidemia (Hypertriglyceridaemia)	40	74	114
Obesity (BMI>26)	26	47	73
Hypertension	10	12	22
Coronary artery disease (h/o angina,	8	5	13

arrhythmia, MI, i.e., atherosclerosis)			
Hyperuricaemia	0	2	02

BMI –Body Mass Index

- 5 Table 6 illustrates the collective totals of the number of IRS components within the subject group.

Table 6

1 component	114	T
2 component	80	73 (T+O); 4 (T+H); 3 (T+I)
3 component	24	6 (T+O+I); 14 (T+O+H); 2 (T+I+H); 2 (T+O+U)
4 component	4	T+O+I+H

10

T = Raised Triglycerides (Dyslipidemia), O = Obesity, H = Hypertension, I = CAD/IHD, U = Hyperuricaemia

15 Preliminary data are presented below demonstrating reductions in serum triglyceride levels with sildenafil treatment. Falls in serum triglyceride levels (in mg/dl) of 100.3; 67.3; and 23.9 were observed for the 10, 25 and 50mg sildenafil groups respectively, compared to 19.9mg/dl fall in the placebo group. This represents a fall of about 40%; 31% and 12% fall on treatment with sildenafil from baseline values (mg/dl) of 255, 213 and 191 compared to 10.7% from a baseline
20 of 185mg/dl for placebo.

The reduction of serum triglycerides that was seen in the sildenafil group was statistically significantly different compared to placebo ($p=0.0457$). There was also a trend seen in HDL ($p=0.0539$). These changes, in non-diabetic subjects
25 who have many features of the IRS, are consistent with improvements in the insulin resistance syndrome.

Further these results are consistent with improvements in insulin resistance in non-diabetic subjects who have many features of the IRS when treated with
30 sildenafil. Thus according to a further aspect the present invention additionally comprises treatment of insulin resistance with a selective pyrazolopyrimidinone cGMP PDE5 inhibitor (as defined hereinbefore).

Clinical Trial Data 2

Adult subjects with Diabetes Mellitus were treated chronically with sildenafil citrate
5 in an out-patient, multicentre study. Subjects were taking several different
glucose-lowering agents (including, but not limited to, metformin, insulin, or
sulfonylureas) or were treated with diet alone. Glycosylated haemoglobin (HbA1c)
was determined prior to treatment and at the end of the study. Glycosylated
haemoglobin (HbA1c) is a recognised measure of chronic glucose control. In this
10 study a significant improvement in glucose control was observed in said subjects
with type 2 diabetes mellitus when treated with sildenafil citrate (Viagra™). These
significant improvements were consistently observed across the subject group
irrespective of their background therapy.

15

These results are consistent with improvements in the IRS in adult subjects when
treated with sildenafil. Further these results are consistent with improvements in
glucose control in patients having type 2 diabetes mellitus when treated with
sildenafil. Thus the present invention provides a method of treatment of type 2
20 diabetes mellitus comprising treating a subject in need of such treatment with a
selective pyrazolopyrimidinone cGMP PDE5 inhibitor (as defined hereinbefore)
and especially sildenafil. In particular said treatment is effected by the oral route.

The results of clinical trial 2 are supporting for the use of a selective cGMP PDE5
25 inhibitor as defined hereinbefore, and especially sildenafil for the treatment of IGT.

Additionally these results are consistent with improvements in the IRS in adult
subjects when treated with a combination of sildenafil and glucose-lowering
agents. Thus the present invention additionally comprises the combination of a
30 selective PDE5 inhibitor and a glucose-lowering agent for the treatment of the
IRS. In particular said combined treatment is effected by the oral route.

According to a further aspect the present invention provides a combination therapy suitable for use in the treatment of the IRS, IR, type 2 diabetes mellitus, impaired glucose tolerance (IGT), hyperuricaemia and/or gout, dyslipidemia, the procoagulant state or truncal obesity wherein said combination comprises a selective cGMP PDE5 inhibitor, preferably a pyrazolopyrimidinone, especially sildenafil with an additional agent active as defined hereinbefore and preferably (16), (40), (41), (42), (50), (52), (53) and/or (54), more preferably one or more of : weight loss agents, sulfonyl ureas, insulin, Rezulin, Avandia, Actos, Glipizide, Metformin, Acarbose, rosiglitazone, pioglitazone, farglitazar, LY333531, CS011, PPAR-alpha agonists, and/or CP-470711.

According to a yet further aspect said combination treatment(s) is/are effected orally and further may be in the form of a kit.

Taken together, the results from both the animal and human trials are consistent with improvements in the IRS as well as in clinical parameters associated with the IRS. That is, improvements in triglycerides in both diabetic and non-diabetic experiments as well as improvement in glucose in those with diabetes support the activity of PDE5 inhibitor compounds, including but not limited to sildenafil, on the IRS.

CLAIMS

1. Use of a selective cGMP PDE5 inhibitor or a pharmaceutical composition
5 thereof in the preparation of a medicament for the curative, palliative or prophylactic treatment of the insulin resistance syndrome wherein the insulin resistance syndrome means the concomitant existence in a subject of two or more of : dyslipidemia; hypertension; type 2 diabetes mellitus, impaired glucose tolerance (IGT) or a family history of diabetes;
10 hyperuricaemia and/or gout; a pro-coagulant state; atherosclerosis; or truncal obesity.
2. Use according to claim 1 wherein the subject has type 2 diabetes mellitus, impaired glucose tolerance (IGT) or a family history of diabetes and at least
15 one or more of : dyslipidemia; hypertension; hyperuricaemia and/or gout; a pro-coagulant state; atherosclerosis; or truncal obesity.
3. Use according to claim 1 wherein the subject has type 2 diabetes mellitus, impaired glucose tolerance (IGT) or a family history of diabetes and at least
20 two or more of : dyslipidemia; hypertension; hyperuricaemia and/or gout; a pro-coagulant state; atherosclerosis; or truncal obesity.
4. Use according to claim 1 wherein the subject has type 2 diabetes mellitus, impaired glucose tolerance or a family history of diabetes and at least three or
25 more of : dyslipidemia; hypertension; hyperuricaemia and/or gout; a pro-coagulant state; atherosclerosis; or truncal obesity.
5. Use according to claim 1 wherein the subject has type 2 diabetes mellitus, impaired glucose tolerance or a family history of diabetes and at least four or
30 more of : dyslipidemia; hypertension; hyperuricaemia and/or gout; a pro-coagulant state; atherosclerosis; or truncal obesity.
6. Use according to claim 1 wherein the subject has type 2 diabetes mellitus,

impaired glucose tolerance or a family history of diabetes and at least five or more of : dyslipidemia; hypertension; hyperuricaemia and/or gout; a pro-coagulant state; atherosclerosis; or truncal obesity.

- 5 7. Use according to claim 1 wherein the subject has type 2 diabetes mellitus or impaired glucose tolerance and dyslipidemia and hypertension and truncal obesity.
8. Use according to claim 1 wherein the subject has three or more of: type 2
10 diabetes mellitus, impaired glucose tolerance (IGT) or having a family history of diabetes; dyslipidemia; hypertension; hyperuricaemia and/or gout; a pro-coagulant state; atherosclerosis; or truncal obesity.
9. Use according to claim 1 wherein the subject of four or more of: type 2
15 diabetes mellitus, impaired glucose tolerance (IGT) or having a family history of diabetes; dyslipidemia; hypertension; hyperuricaemia and/or gout; a pro-coagulant state; atherosclerosis; or truncal obesity.
10. Use according to claim 1 wherein the subject has five or more of: type 2
20 diabetes mellitus, impaired glucose tolerance (IGT) or having a family history of diabetes; dyslipidemia; hypertension; hyperuricaemia and/or gout; a pro-coagulant state; atherosclerosis; or truncal obesity.
11. Use according to claim 1 wherein the subject has dyslipidemia,
25 hypertension, type 2 diabetes mellitus or impaired glucose tolerance (IGT) and truncal obesity.
12. Use according to any of claims 1 to 11 wherein the selective cGMP PDE5
30 inhibitor is selected from sildenafil, 5-(2-ethoxy-5-morpholinoacetylphenyl)-1-ethyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, 3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-n-propoxyphenyl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, 3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, 5-[2-ethoxy-5-(4-ethylpiperazin-1-

ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-2,6-dihydro-7H-
 pyrazolo[4,3-*d*]pyrimidin-7-one, 5-(5-Acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-
 ethyl-3-azetidiny)-2,6-dihydro-7H-pyrazolo[4,3-*d*]pyrimidin-7-one, (6R,12aR)-
 2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)
 5 pyrazino[2',1':6,1]pyrido[3,4-*b*]indole-1,4-dione; 2-[2-ethoxy-5-(4-ethyl-
 piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-
f][1,2,4]triazin-4-one and 1-[[3-(3,4-dihydro-5-methyl-4-oxo-7-
 propylimidazolo[5,1-*f*]-as-triazin-2-yl)-4-ethoxyphenyl]sulphonyl]-4-
 ethylpiperzine or a pharmaceutically acceptable salt, solvate, pro-drug,
 10 polymorph or a pharmaceutical composition thereof.

13. The use according to any of claims 1 to 12 wherein the selective cGMP
 PDE5 inhibitor is selected from sildenafil, 5-[2-ethoxy-5-(4-ethylpiperazin-1-
 ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-2,6-dihydro-7H-
 15 pyrazolo[4,3-*d*]pyrimidin-7-one or 5-(5-acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-
 (1-ethyl-3-azetidiny)-2,6-dihydro-7H-pyrazolo[4,3-*d*]pyrimidin-7-one.

14. Use of a selective cGMP PDE5 inhibitor or a pharmaceutical composition
 thereof in the preparation of a medicament for the curative, palliative or
 20 prophylactic treatment of the insulin resistance syndrome wherein the
 insulin resistance syndrome means the concomitant existence in a subject
 of dyslipidemia and hypertension and type 2 diabetes mellitus or impaired
 glucose tolerance (IGT), and truncal obesity and wherein the selective
 cGMP PDE5 inhibitor is sildenafil, 5-(2-ethoxy-5-morpholinoacetylphenyl)-1-
 25 ethyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-*d*]pyrimidin-7-one, 3-ethyl-5-
 [5-(4-ethylpiperazin-1-ylsulphonyl)-2-n-propoxyphenyl]-2-(pyridin-2-
 yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-*d*]pyrimidin-7-one, 3-ethyl-5-[5-(4-
 ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-2-(pyridin-2-
 yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-*d*]pyrimidin-7-one, 5-[2-ethoxy-5-(4-
 30 ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-2,6-
 dihydro-7H-pyrazolo[4,3-*d*]pyrimidin-7-one, 5-(5-Acetyl-2-butoxy-3-
 pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidiny)-2,6-dihydro-7H-pyrazolo[4,3-
d]pyrimidin-7-one, (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-
 methylenedioxyphenyl) -pyrazino[2',1':6,1]pyrido[3,4-*b*]indole-1,4-dione; 2-

[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one and 1-[[3-(3,4-dihydro-5-methyl-4-oxo-7-propylimidazolo[5,1-f]-as-triazin-2-yl)-4-ethoxyphenyl]sulphonyl]-4-ethylpiperzine or a pharmaceutically acceptable salt, solvate, pro-drug, polymorph or a pharmaceutical composition thereof.

15. Use according to claim 14 wherein the selective cGMP PDE5 inhibitor is selected from sildenafil, 5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one or 5-(5-acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidiny)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one.
16. Use according to claim 14 wherein the selective cGMP PDE5 inhibitor is sildenafil.
17. Use of sildenafil or a pharmaceutical composition thereof in the preparation of a medicament for the curative, palliative or prophylactic treatment of the insulin resistance syndrome in a subject having type 2 diabetes mellitus, impaired glucose tolerance (IGT) or a family history of diabetes and at least one or more of : dyslipidemia; hypertension; hyperuricaemia and/or gout; a pro-coagulant state; atherosclerosis; or truncal obesity.
18. Use of sildenafil or a pharmaceutical composition thereof in the preparation of a medicament for the curative, palliative or prophylactic treatment of the insulin resistance syndrome in a subject having : type 2 diabetes mellitus, impaired glucose tolerance (IGT) or a family history of diabetes; dyslipidemia; hypertension; and truncal obesity.
19. Use of sildenafil or a pharmaceutical composition thereof in combination with other agents as indicated in the preparation of a medicament for the curative, palliative or prophylactic treatment of the insulin resistance syndrome in a subject having : type 2 diabetes mellitus, impaired glucose tolerance (IGT) or a family history of diabetes; dyslipidemia; hypertension; and truncal obesity.

20. A method of treating the insulin resistance syndrome in a mammal comprising administering to said mammal an effective amount of a selective cGMP PDE5 inhibitor or a pharmaceutically acceptable salt, solvate or composition thereof.
21. A method of treating the insulin resistance syndrome in a mammal comprising administering to said mammal an effective amount of a selective cGMP PDE5 inhibitor or a pharmaceutically acceptable salt, solvate or composition thereof wherein said administration comprises daily dosing and wherein said dosing can be in the form of single, multiple or divided doses.
22. A method of treating the insulin resistance syndrome in a mammal comprising administering to said mammal an effective amount of a selective cGMP PDE5 inhibitor or a pharmaceutically acceptable salt, solvate or composition thereof wherein said administration comprises daily dosing for 5 or more days wherein said daily dosing can be in the form of single, multiple or divided doses.
23. A method of treating the insulin resistance syndrome in a mammal comprising administering to said mammal an effective amount of a selective cGMP PDE5 inhibitor or a pharmaceutically acceptable salt, solvate or composition thereof wherein said administration comprises continuous dosing for 5 or more days wherein said continuous dosing can be in the form of single or multiple continuous release doses.
24. A method of treatment the insulin resistance syndrome in a mammal comprising administering to said mammal an effective amount of a selective cGMP PDE5 inhibitor in combination with one or more further components selected from one or more of : protein kinase inhibitors; and or one or more activators or AMP-activated protein kinase; and/or one or more weight loss agents; and/or insulin; and/or one or more PPAR-gamma agonists; and/or one or more PPAR-alpha agonists; and/or one or more

dual PPAR-alpha/PPAR-gamma agonists; one or more sorbitol dehydrogenase inhibitors; one or more aldose reductase inhibitors; one or more insulin sensitising agents; one or more hypoglycaemic agents.

5

25. Use of a selective pyrazolopyrimidinone cGMP PDE5 inhibitor or a pharmaceutical composition thereof in the preparation of a medicament for the curative, palliative or prophylactic treatment of type 2 diabetes mellitus.

10

26. Use according to claim 25 wherein the selective pyrazolopyrimidinone cGMP PDE5 inhibitor is selected from sildenafil, 5-(2-ethoxy-5-morpholinoacetylphenyl)-1-ethyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-*d*]pyrimidin-7-one, 3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-n-propoxyphenyl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-*d*]pyrimidin-7-one, 3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-*d*]pyrimidin-7-one, 5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-2,6-dihydro-7H-pyrazolo[4,3-*d*]pyrimidin-7-one, 5-(5-Acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidiny)-2,6-dihydro-7H-pyrazolo[4,3-*d*]pyrimidin-7-one, or a pharmaceutically acceptable salt, solvate, pro-drug, polymorph or a pharmaceutical composition thereof.

15

20

25

27. The use according to claims 26 or 27 wherein the selective pyrazolopyrimidinone cGMP PDE5 inhibitor is selected from sildenafil, 5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-2,6-dihydro-7H-pyrazolo[4,3-*d*]pyrimidin-7-one or 5-(5-acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidiny)-2,6-dihydro-7H-pyrazolo[4,3-*d*]pyrimidin-7-one.

30

28. Use of a pyrazolopyrimidinone selective cGMP PDE5 inhibitor or a pharmaceutical composition thereof in the preparation of a medicament for the curative, palliative or prophylactic treatment of the type 2 diabetes mellitus wherein the cGMP PDE5 inhibitor is selected from sildenafil, 5-(2-

ethoxy-5-morpholinoacetylphenyl)-1-ethyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, 3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-n-propoxyphenyl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, 3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, 5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, 5-(5-Acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidiny)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one or a pharmaceutically acceptable salt, solvate, pro-drug, polymorph or a pharmaceutical composition thereof.

29. Use according to claim 28 wherein the selective pyrazolopyrimidinone cGMP PDE5 inhibitor is sildenafil.
30. Use of sildenafil or a pharmaceutically acceptable salt or a pharmaceutical composition thereof in the preparation of a medicament for the curative, palliative or prophylactic treatment of type 2 diabetes mellitus.
31. Use of sildenafil or a pharmaceutical composition thereof in the preparation of a medicament for the curative, palliative or prophylactic treatment of type 2 diabetes mellitus.
32. Use of sildenafil or a pharmaceutical composition thereof in combination with other agents as indicated in the preparation of a medicament for the curative, palliative or prophylactic treatment of type 2 diabetes mellitus.
33. A method of treating type 2 diabetes mellitus in a mammal comprising administering to said mammal an effective amount of sildenafil or a pharmaceutically acceptable salt, solvate or composition thereof.
34. A method of treating type 2 diabetes mellitus in a mammal comprising administering to said mammal an effective amount of sildenafil or a pharmaceutically acceptable salt, solvate or composition thereof wherein

said administration comprises daily dosing and wherein said dosing can be in the form of single, multiple or divided doses.

35. A method of treating type 2 diabetes mellitus in a mammal comprising
5 administering to said mammal an effective amount of sildenafil or a pharmaceutically acceptable salt, solvate or composition thereof wherein said administration comprises daily dosing for 5 or more days wherein said daily dosing can be in the form of single, multiple or divided doses.
- 10 36. A method of treating type 2 diabetes mellitus in a mammal comprising administering to said mammal an effective amount of sildenafil or a pharmaceutically acceptable salt, solvate or composition thereof wherein said administration comprises continuous dosing for 5 or more days wherein said continuous dosing can be in the form of single or multiple continuous
15 release doses.
37. A method of treating type 2 diabetes mellitus in a mammal comprising administering to said mammal an effective amount of sildenafil in combination with one or more further components selected from one or
20 more of : protein kinase inhibitors; and or one or more activators or AMP-activated protein kinase; and/or one or more weight loss agents; and/or insulin; and/or one or more PPAR-gamma agonists; and/or one or more PPAR-alpha agonists; and/or one or more dual PPAR-alpha/PPAR-gamma agonists; one or more sorbitol dehydrogenase inhibitors; one or more
25 aldose reductase inhibitors one or more insulin sensitising agents; one or more hypoglycaemic agents.
38. Use of a selective pyrazolopyrimidinone cGMP PDE5 inhibitor or a pharmaceutical composition thereof in the preparation of a medicament for
30 the curative, palliative or prophylactic treatment of impaired glucose tolerance (IGT) .
39. Use according to claim 38 wherein the selective pyrazolopyrimidinone cGMP PDE5 inhibitor is selected from sildenafil, 5-(2-ethoxy-5-

morpholinoacetylphenyl)-1-ethyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-
 d]pyrimidin-7-one, 3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-n-
 propoxyphenyl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-
 d]pyrimidin-7-one, 3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-
 5 methoxyethoxy)pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-
 pyrazolo[4,3-d]pyrimidin-7-one, 5-[2-ethoxy-5-(4-ethylpiperazin-1-
 ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-2,6-dihydro-7H-
 pyrazolo[4,3-d]pyrimidin-7-one, 5-(5-Acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-
 ethyl-3-azetidiny)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, or a
 10 pharmaceutically acceptable salt, solvate, pro-drug, polymorph or a
 pharmaceutical composition thereof.

40. The use according to claims 38 or 39 wherein the selective
 pyrazolopyrimidinone cGMP PDE5 inhibitor is selected from sildenafil, 5-[2-
 15 ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(2-
 methoxyethyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one or 5-(5-acetyl-
 2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidiny)-2,6-dihydro-7H-
 pyrazolo[4,3-d]pyrimidin-7-one.

20 41. Use of a pyrazolopyrimidinone selective cGMP PDE5 inhibitor or a
 pharmaceutical composition thereof in the preparation of a medicament for
 the curative, palliative or prophylactic treatment of impaired glucose
 tolerance (IGT) wherein the cGMP PDE5 inhibitor is selected from
 sildenafil, 5-(2-ethoxy-5-morpholinoacetylphenyl)-1-ethyl-3-n-propyl-1,6-
 25 dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, 3-ethyl-5-[5-(4-ethylpiperazin-1-
 ylsulphonyl)-2-n-propoxyphenyl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-
 pyrazolo[4,3-d]pyrimidin-7-one, 3-ethyl-5-[5-(4-ethylpiperazin-1-
 ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-
 dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, 5-[2-ethoxy-5-(4-ethylpiperazin-1-
 30 1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-2,6-dihydro-7H-
 pyrazolo[4,3-d]pyrimidin-7-one, 5-(5-Acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-
 (1-ethyl-3-azetidiny)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one or a
 pharmaceutically acceptable salt, solvate, pro-drug, polymorph or a

pharmaceutical composition thereof.

42. Use according to claim 41 wherein the selective pyrazolopyrimidinone cGMP PDE5 inhibitor is sildenafil.
- 5 43. Use of sildenafil or a pharmaceutically acceptable salt or a pharmaceutical composition thereof in the preparation of a medicament for the curative, palliative or prophylactic treatment of impaired glucose tolerance (IGT).
- 10 44. Use of sildenafil or a pharmaceutical composition thereof in the preparation of a medicament for the curative, palliative or prophylactic treatment of impaired glucose tolerance (IGT).
- 15 45. Use of sildenafil or a pharmaceutical composition thereof in combination with other agents as indicated in the preparation of a medicament for the curative, palliative or prophylactic treatment of impaired glucose tolerance (IGT).
- 20 46. A method of treating impaired glucose tolerance (IGT) in a mammal comprising administering to said mammal an effective amount of sildenafil or a pharmaceutically acceptable salt, solvate or composition thereof.
- 25 47. A method of treatment of impaired glucose tolerance (IGT) in a mammal comprising administering to said mammal an effective amount of sildenafil in combination with one or more further components selected from one or more of : protein kinase inhibitors; and or one or more activators or AMP-activated protein kinase; and/or one or more weight loss agents; and/or insulin; and/or one or more PPAR-gamma agonists; and/or one or more PPAR-alpha agonists; and/or one or more dual PPAR-alpha/PPAR-gamma agonists; one or more sorbitol dehydrogenase inhibitors; one or more aldose reductase inhibitors; one or more insulin sensitising agents; one or more hypoglycaemic agents.
- 30 48. Use of a selective pyrazolopyrimidinone cGMP PDE5 inhibitor or a

pharmaceutical composition thereof in the preparation of a medicament for the curative, palliative or prophylactic treatment of insulin resistance (IR).

49. Use according to claim 48 wherein the selective pyrazolopyrimidinone cGMP PDE5 inhibitor is selected from sildenafil, 5-(2-ethoxy-5-morpholinoacetylphenyl)-1-ethyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, 3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-n-propoxyphenyl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, 3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, 5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, 5-(5-Acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidiny)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, or a pharmaceutically acceptable salt, solvate, pro-drug, polymorph or a pharmaceutical composition thereof.
50. The use according to claims 48 or 49 wherein the selective pyrazolopyrimidinone cGMP PDE5 inhibitor is selected from sildenafil, 5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one or 5-(5-acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidiny)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one.
51. Use of a pyrazolopyrimidinone selective cGMP PDE5 inhibitor or a pharmaceutical composition thereof in the preparation of a medicament for the curative, palliative or prophylactic treatment of insulin resistance (IR) wherein the cGMP PDE5 inhibitor is selected from sildenafil, 5-(2-ethoxy-5-morpholinoacetylphenyl)-1-ethyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, 3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-n-propoxyphenyl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, 3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, 5-[2-ethoxy-5-(4-ethylpiperazin-1-

ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, 5-(5-Acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidiny)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one or a pharmaceutically acceptable salt, solvate, pro-drug, polymorph or a pharmaceutical composition thereof.

52. Use according to claim 51 wherein the selective pyrazolopyrimidinone cGMP PDE5 inhibitor is sildenafil.
53. Use of sildenafil or a pharmaceutically acceptable salt or a pharmaceutical composition thereof in the preparation of a medicament for the curative, palliative or prophylactic treatment of insulin resistance (IR).
54. Use of sildenafil or a pharmaceutical composition thereof in the preparation of a medicament for the curative, palliative or prophylactic treatment of insulin resistance (IR).
55. Use of sildenafil or a pharmaceutical composition thereof in combination with other agents as indicated in the preparation of a medicament for the curative, palliative or prophylactic treatment of insulin resistance (IR).
56. A method of treating insulin resistance (IR) in a mammal comprising administering to said mammal an effective amount of sildenafil or a pharmaceutically acceptable salt, solvate or composition thereof.
57. A method of treatment of insulin resistance (IR) in a mammal comprising administering to said mammal an effective amount of sildenafil in combination with one or more further components selected from one or more of : protein kinase inhibitors; and or one or more activators or AMP-activated protein kinase; and/or one or more weight loss agents; and/or insulin; and/or one or more PPAR-gamma agonists; and/or one or more PPAR-alpha agonists; and/or one or more dual PPAR-alpha/PPAR-gamma agonists; one or more sorbitol dehydrogenase inhibitors; one or more aldose reductase inhibitors; one or more insulin sensitising agents; one or more hypoglycaemic

agents.

58. A method of treatment the insulin resistance syndrome in a mammal comprising administering to said mammal an effective amount of a selective cGMP PDE5 inhibitor in combination with one or more further components selected from one or more of : protein kinase inhibitors; and or one or more activators or AMP-activated protein kinase; and/or one ore more weight loss agents; and/or insulin; and/or one or more PPAR-gamma agonists; and/or one or more PPAR-alpha agonists; and/or one or more dual PPAR-alpha/PPAR-gamma agonists; one or more sorbitol dehydrogenase inhibitors; one or more aldose reductase inhibitors; one or more insulin sensitising agents; one or more hypoglycaemic agents.
59. A method of treatment the insulin resistance syndrome in a mammal comprising administering to said mammal an effective amount of a selective cGMP PDE5 inhibitor, preferably a pyrazolopyrimidinone, especially sildenafil in combination with one or more further components selected from one or more of : weight loss agents, sulfonyl ureas, insulin, Rezulin, Avandia, Actos, Glipizide, Metformin, Acarbose, rosiglitazone, pioglitazone, farglitazar; LY333531, CS011, PPAR-alpha agonists, and/or CP-470711.
60. Use of a selective cGMP PDE5 inhibitor or a pharmaceutical composition thereof in the preparation of a medicament for the curative, palliative or prophylactic treatment of the insulin resistance syndrome wherein the insulin resistance syndrome means the concomitant existence in a polygenic subject of two or more of : dyslipidemia; hypertension; type 2 diabetes mellitus, impaired glucose tolerance (IGT) or a family history of diabetes; hyperuricaemia and/or gout; a pro-coagulant state; atherosclerosis; or truncal obesity.
61. A method of treatment according to any of claims 37, 47 or 57 wherein said method comprises administering to a mammal in need of such treatment an effective amount of a selective pyrazolopyrimidinone cGMP PDE5 inhibitor,

especially sildenafil in combination with one or more further components selected from one or more of : weight loss agents, sulfonyl ureas, insulin, Rezulin, Avandia, Actos, Glipizide, Metformin, Acarbose, rosiglitazone, pioglitazone, farglitazar, LY333531, CS011, PPAR-alpha agonists, and/or CP-470711.

62. Use according to any of claims 1 to 32, 38 to 45, 48 to 55 or 60 or a method according to any of claims 33 to 37, 46, 47, 56 to 59 or 61 wherein said use or method of treatment is effected via oral administration.

10

63. Use according to any of the preceding claims wherein the cGMP PDE5 inhibitor has an IC_{50} against PDE5 of less than 100nM and a selectivity ratio of PDE5 over PDE3 of more than 100.

15

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 February 2002 (21.02.2002)

PCT

(10) International Publication Number
WO 02/013798 A3

(51) International Patent Classification⁷: **A61K 31/00**,
31/505, 31/5355, 31/535, 31/4985, 31/495, 31/53, 38/28,
45/06, A61P 3/04, 3/06, 3/08, 3/10, 9/12, 9/10, 7/04

(74) Agent: **WOOD, David, J.** Pfizer Limited, Ramsgate Road,
Sandwich, Kent CT13 9NJ (GB).

(21) International Application Number: PCT/IB01/01428

(22) International Filing Date: 6 August 2001 (06.08.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/224,928 11 August 2000 (11.08.2000) US
0030649.8 15 December 2000 (15.12.2000) GB
60/266,083 2 February 2001 (02.02.2001) US
0106465.8 15 March 2001 (15.03.2001) GB
0106468.2 15 March 2001 (15.03.2001) GB
0117134.7 13 July 2001 (13.07.2001) GB

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(71) Applicant (*for GB only*): **PFIZER LIMITED** [GB/GB];
Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(88) Date of publication of the international search report:
23 January 2003

(71) Applicant (*for all designated States except GB, US*):
PFIZER INC. [US/US]; 235 East 42nd Street, New York,
NY 10017 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **FRYBURG, David, Albert** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340 (US). **GIBBS, Earl, Michael** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340 (US). **KOPPIKER, Nandan, Parmanand** [IN/GB]; Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TREATMENT OF THE INSULIN RESISTANCE SYNDROME WITH SELECTIVE CGMP PDE5 INHIBITORS

(57) Abstract: Use of a selective cGMP PDE5 inhibitor or a pharmaceutical composition thereof in the preparation of a medicament for the curative, palliative or prophylactic treatment of the insulin resistance syndrome wherein the insulin resistance syndrome means the concomitant existence in a subject of two or more of: dyslipidemia; hypertension; type 2 diabetes mellitus, impaired glucose tolerance (IGT) or a family history of diabetes; hyperuricaemia and/or gout; a pro-coagulant state; atherosclerosis; or truncal obesity wherein said use can occur alone or in combination with other agents to treat the insulin resistance syndrome or individual aspects of the insulin resistance syndrome.

WO 02/013798 A3

INTERNATIONAL SEARCH REPORT

Inten ... if Application No

PCT/IB 01/01428

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/00 A61K31/505 A61K31/535 A61K31/535 A61K31/4985
 A61K31/495 A61K31/53 A61K38/28 A61K45/06 A61P3/04
 A61P3/06 A61P3/08 A61P3/10 A61P9/12 A61P9/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data, MEDLINE, SCISEARCH, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X A P,X P,A	<p>WO 99 51574 A (HIRAMURA TAKAHIRO ;OKU TERUO (JP); ONOMURA OSAMU (JP); IMOTO TAKAF) 14 October 1999 (1999-10-14) abstract</p> <p>& EP 1 070 705 A (FUJISAWA PHARMACEUTICAL CO.) 24 January 2001 (2001-01-24) abstract</p> <p>page 2, line 5 - line 45 page 8, line 7 - line 41 page 25, line 51 -page 26, line 57 claim 8</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p>	<p>1-11, 20-23, 60,62,63 25-31, 33-36, 38-44,46 1-11, 20-23, 60,62,63 25-31, 33-36, 38-44,46</p>

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

8 July 2002

Date of mailing of the international search report

18. 07. 2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Cielen, E

INTERNATIONAL SEARCH REPORT

Intern. Application No.

PCT/TB 01/01428

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61P7/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X A	<p>EP 0 995 742 A (FUJISAWA PHARMACEUTICAL CO) 26 April 2000 (2000-04-26)</p> <p>abstract</p> <p>page 2, line 5 - line 30 page 12, line 26 - line 38 page 23, line 36 - page 24, line 44 page 208, line 49 - page 209, line 9 claims 13,14</p> <p style="text-align: center;">--- -/--</p>	<p>1-11, 20-23, 60,62,63</p> <p>25-31, 33-36, 38-44,46</p>

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

8 July 2002

Date of mailing of the international search report

18. 07. 2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Cielen, E

INTERNATIONAL SEARCH REPORT

Interr Application No

PCT/IB 01/01428

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X A	EP 0 882 718 A (FUJISAWA PHARMACEUTICAL CO) 9 December 1998 (1998-12-09) abstract page 3, line 5 - line 42 page 26, line 57 -page 27, line 34 page 28, line 37 - line 50 page 132, line 21 -page 135, line 29 claims 1-4,7-12,21-23 ---	1-11, 20-23, 60,62,63 25-31, 33-36, 38-44,46
X A	WO 00 34277 A (HAMASHIMA HITOSHI ;HIRAMURA TAKAHIRO (JP); ABE YOSHITO (JP); OKU T) 15 June 2000 (2000-06-15) abstract	1-11, 20-23, 60,62,63 25-31, 33-36, 38-44,46
E	& EP 1 136 492 A (FUJISAWA PHARMACEUTICAL CO.) 26 September 2001 (2001-09-26) abstract page 2, line 5 - line 34 page 17, line 19 -page 18, line 26 page 81, line 1 - line 25 claims 10-12 ---	1-11, 20-23, 60,62,63
X	EP 0 463 756 A (PFIZER LTD ;PFIZER (US)) 2 January 1992 (1992-01-02) cited in the application abstract page 3, line 1 - line 14 page 4, line 15 - line 29 page 7, line 18 - line 49 claims 4,7 ---	1,2,13, 20-23, 48-54, 56,62,63
X	WO 98 49166 A (BUNNAGE MARK EDWARD ;MATHIAS JOHN PAUL (GB); STREET STEPHEN DEREK) 5 November 1998 (1998-11-05) cited in the application page 1, line 3 - line 20 page 5, line 27 - line 28 page 20, line 6 - line 10 page 21, line 10 -page 23, line 8 claims 5,10,12,13,15 ---	1,12, 20-23, 48,49, 51,62,63
X	WO 96 38131 A (GLAXO GROUP LTD ;BUTLER JAMES MATTHEW (GB)) 5 December 1996 (1996-12-05) abstract page 4, line 15 - line 21 page 7, line 35 -page 8, line 35 example 1 claims 23,26 ---	1,12, 20-23, 60,62,63

-/--

INTERNATIONAL SEARCH REPORT

Intern Application No

PCT/TB 01/01428

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	BEERS M.H.; BERKOW R.: "The Merck Manual of Diagnosis and Therapy, Seventeenth Edition" 1999, MERCK RESEARCH LABORATORIES, WHITEHOUSE STATION, N.J. XP002192621 page 165 -page 177 page 1663 ---	
A	NORMAN P: "IC-351 ICOS CORP" CURRENT OPINION IN CPNS INVESTIGATIONAL DRUGS, PHARMA PRESS, LONDON,, GB, vol. 1, no. 2, 1999, pages 268-271, XP001021217 ISSN: 1464-844X the whole document ---	
P,X	WO 01 19357 A (BAYER AG ;BISCHOFF ERWIN (DE); BISCHOFF HILMAR (DE); GIULIANO FRAN) 22 March 2001 (2001-03-22) abstract page 3, line 17 - line 31 page 4, line 21 - line 26 page 5, line 9 - line 15 page 10, line 27 -page 11, line 10 page 12, line 19 - line 26 page 26, line 9 - line 14 page 27, line 30 - line 31 page 30, line 8 page 33, line 2 - line 9 page 34, line 12 - line 14 claims 1,13-15 ---	1-3,8, 12,13, 17, 20-23, 25-36, 60,62,63
P,X	EP 1 088 824 A (PFIZER PROD INC) 4 April 2001 (2001-04-04) abstract page 2, line 5 - line 9 page 8, line 1 - line 47 page 10, line 42 -page 11, line 50 page 14, line 1 - line 9 page 15, line 13 - line 18 page 15, line 39 - line 44 page 18, line 14 - line 50 claims 11,13,14 --- -/--	1-23, 25-36, 38-46, 48-56, 60,62,63

INTERNATIONAL SEARCH REPORT

Intern Application No

PCT/IB 01/01428

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>WO 00 56719 A (SQUIBB BRISTOL MYERS CO) 28 September 2000 (2000-09-28)</p> <p>page 3, line 11 - line 18 page 49, line 1 - line 29 page 50, line 28 -page 51, line 11 page 52, line 30 -page 53, line 29 page 54, line 1 - line 3</p> <p>---</p>	<p>1-4,8,9, 12,13, 17, 20-23, 25-36, 60,62,63</p>
E	<p>WO 01 78781 A (WATKINS CRYSTAL C ;FERRIS CHRISTOPHER D (US); SNYDER SOLOMON M (US) 25 October 2001 (2001-10-25) abstract page 9, line 11 - line 29 page 12, line 14 - line 19 page 17, line 29 -page 18, line 7 page 18, line 28 -page 19, line 2 page 72, line 26 -page 73, line 4 page 74, line 10 page 76, line 1 - line 6 page 75, line 1 - line 4 page 75, line 25 - line 31 claims 44-53</p> <p>---</p>	<p>25-37, 61-63</p>
P,A	<p>EP 1 092 719 A (PFIZER LTD ;PFIZER (US)) 18 April 2001 (2001-04-18)</p> <p>page 2, line 5 - line 56 page 3, line 40 - line 44 page 12, line 30 -page 13, line 1 page 14, line 56 - line 58 page 15, line 14 - line 15 page 16, line 26</p> <p>-----</p>	<p>1,12, 20-24, 58,60, 62,63</p>

INTERNATIONAL SEARCH REPORT

II International application No.
PCT/IB 01/01428

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 20-24, 33-37, 46, 47, 56-59, 61 are directed to a method of treatment of the human/animal body, the search for the first invention has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

As a result of the prior review under R. 40.2(e) PCT,
no additional fees are to be refunded.

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☒ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1-12, 14, 19-26, 28, 32, 37-39, 41, 45, 47-49, 51, 55, 57-63 relate to compounds which actually are not well-defined. The use of the definition "a selective cGMP PDE 5 inhibitor", "a prodrug", "in combination with other agents as indicated", "protein kinase inhibitors", "activators of AMP-activated protein kinase", "weight loss agents"; "PPAR gamma agonists", "PPAR alpha agonists", "dual PPAR alpha/PPAR gamma agonists", "sorbitol dehydrogenase inhibitors", "aldose reductase inhibitors", "insulin sensitising agents", "hypoglycemic agents", "sulfonyl ureas", "wherein the cGMP PDE5 inhibitor has an IC50 against PDE5 of less than 100nM and a selectivity ratio of PDE5 over PDE3 of more than 100" in the present context is considered to lead to a lack of clarity within the meaning of Article 6 PCT.

Moreover, the definition of "insulin resistance syndrome" given in claims 1, 8-10 is considered to lead to a lack of clarity within the meaning of Article 6 PCT, since e.g. a combination of hypertension and atherosclerosis could also fall under this definition.

The lack of clarity is such as to render a meaningful complete search impossible. Consequently, the search has been restricted to the compounds specifically mentioned in the claims and their combination with the compounds specifically mentioned in claims 59 and 61.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-12 (partially), 13 (entirely), 14 (partially),
15-19 (entirely), 20-24 (partially),
25-57 (entirely), 58-60 (partially),
61 (entirely), 62-63 (partially)

Use of a selective pyrazolopyrimidinone cGMP PDE5 inhibitor in the preparation of a medicament for the treatment of the insulin resistance syndrome or of type 2 diabetes mellitus or of impaired glucose tolerance or of insulin resistance.

2. Claims: 1-12 (partially), 14 (partially),
20-24 (partially), 58-60 (partially),
62-63 (partially)

Use of
(6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione in the preparation of a medicament for the treatment of the insulin resistance syndrome.

3. Claims: 1-12 (partially), 14 (partially),
20-24 (partially), 58-60 (partially),
62-63 (partially)

Use of
2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one, which is equal to
1-[3-(3,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-f]as-triazin-2-yl)-4-ethoxyphenyl]-sulphonyl-4-ethylpiperazine in the preparation of a medicament for the treatment of the insulin resistance syndrome.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inter al Application No

PC 1/18 01/01428

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9951574	A	14-10-1999	BR 9909440 A	26-12-2000
			CA 2327397 A1	14-10-1999
			CN 1303371 T	11-07-2001
			EP 1070705 A1	24-01-2001
			WO 9951574 A1	14-10-1999

EP 0995742	A	26-04-2000	AU 745081 B2	14-03-2002
			AU 7934598 A	19-01-1999
			BR 9810456 A	25-09-2001
			EP 0995742 A1	26-04-2000
			US 6348474 B1	19-02-2002
			CN 1268942 T	04-10-2000
			WO 9900372 A1	07-01-1999
			TW 426666 B	21-03-2001
			ZA 9805618 A	19-01-1999
			HU 0002046 A2	28-12-2000

EP 0882718	A	09-12-1998	AU 722514 B2	03-08-2000
			AU 1209597 A	28-07-1997
			BR 9612434 A	28-12-1999
			EP 0882718 A1	09-12-1998
			JP 3063162 B2	12-07-2000
			NZ 324834 A	30-11-2001
			US 6166219 A	26-12-2000
			CA 2241186 A1	28-06-1997
			CN 1211238 A	17-03-1999
			HU 9900625 A2	28-06-1999
			WO 9724334 A1	10-07-1997
			JP 2000159749 A	13-06-2000
			TR 9801249 T2	21-10-1998
			US 6352985 B1	05-03-2002
			ZA 9610918 A	08-07-1997
			AU 4400597 A	05-05-1998
			WO 9815530 A1	16-04-1998
			ZA 9708998 A	20-04-1998

WO 0034277	A	15-06-2000	AU 1414100 A	26-06-2000
			BR 9916919 A	15-01-2002
			CN 1335847 T	13-02-2002
			CZ 20011981 A3	16-01-2002
			EP 1136492 A1	26-09-2001
			WO 0034277 A1	15-06-2000
EP 0463756	A	02-01-1992	TR 200101568 T2	22-10-2001
			AT 121403 T	15-05-1995
			AU 626757 B2	06-08-1992
			AU 7915591 A	19-03-1992
			BR 9102560 A	21-01-1992
			CA 2044748 A1	21-12-1991
			CN 1057464 A ,B	01-01-1992
			CS 9101876 A3	15-04-1992
			CY 1971 A	05-09-1997
			DE 69108991 D1	24-05-1995
			DE 69108991 T2	31-08-1995
			DK 463756 T3	25-09-1995
			EG 19651 A	31-10-1995
			EP 0463756 A1	02-01-1992
			ES 2071919 T3	01-07-1995

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/18 01/01428

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0463756 A		FI 913017 A ,B,	21-12-1991
		HK 219496 A	03-01-1997
		HU 61312 A2	28-12-1992
		IE 912094 A1	01-01-1992
		IL 98482 A	27-11-1995
		JP 2087736 C	02-09-1996
		JP 6041133 A	15-02-1994
		JP 7121945 B	25-12-1995
		KR 9406628 B1	23-07-1994
		LU 90360 A9	03-05-1999
		NO 178029 B	02-10-1995
		NZ 238586 A	26-08-1993
		PL 166490 B1	31-05-1995
		PT 98011 A ,B	31-03-1992
		RU 2047617 C1	10-11-1995
		RU 2114114 C1	27-06-1998
		US 5346901 A	13-09-1994
		US 5719283 A	17-02-1998
		US 5250534 A	05-10-1993
		ZA 9104707 A	24-02-1993
WO 9849166 A	05-11-1998	AP 1002 A	14-08-2001
		AU 730670 B2	08-03-2001
		AU 7644598 A	24-11-1998
		BG 103828 A	30-06-2000
		BR 9810233 A	17-10-2000
		CN 1253561 T	17-05-2000
		WO 9849166 A1	05-11-1998
		EP 0977756 A1	09-02-2000
		HR 980222 A1	28-02-1999
		JP 2000510485 T	15-08-2000
		NO 995211 A	25-10-1999
		NZ 338075 A	27-10-2000
		PL 336586 A1	03-07-2000
		SK 144699 A3	12-03-2001
		TR 9902646 T2	22-05-2000
		ZA 9803478 A	25-10-1999
		HU 0001389 A2	28-09-2000
WO 9638131 A	05-12-1996	AT 207344 T	15-11-2001
		AU 6002696 A	18-12-1996
		DE 69616313 D1	29-11-2001
		DE 69616313 T2	18-04-2002
		WO 9638131 A1	05-12-1996
		EP 0828479 A1	18-03-1998
		ES 2167566 T3	16-05-2002
		US 5985326 A	16-11-1999
WO 0119357 A	22-03-2001	DE 19944161 A1	22-03-2001
		AU 7652400 A	17-04-2001
		WO 0119357 A2	22-03-2001
		EP 1216039 A2	26-06-2002
EP 1088824 A	04-04-2001	BR 0004582 A	17-04-2001
		EP 1088824 A2	04-04-2001
		JP 2001131181 A	15-05-2001
		US 6399601 B1	04-06-2002

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 01/01428

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 0056719	A	28-09-2000	AU	3732700 A	09-10-2000
			CN	1344257 T	10-04-2002
			EP	1165521 A1	02-01-2002
			WO	0056719 A1	28-09-2000
			US	6316438 B1	13-11-2001
WO 0178781	A	25-10-2001	AU	5714601 A	30-10-2001
			WO	0178781 A2	25-10-2001
EP 1092719	A	18-04-2001	BR	0004779 A	29-05-2001
			EP	1092719 A2	18-04-2001
			JP	2001151778 A	05-06-2001

THIS PAGE BLANK (USPTO)